Sentinel Node Procedure for Breast Cancer: training, safety, reliability and follow-up aspects by Kanter, A.Y. de
Sentinel Node Procedure for Breast Cancer: 
training,  safety, reliability and follow-up aspects 
Printed by:  
Optima Grafische Communicatie, Rotterdam 
For the chapters in this thesis that are based on published papers copyright remains with the 
publishers.
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or 
transmitted in any form or by any means, electronically, mechanically, by photocopying or otherwise, 
without the prior written permission of the authors and the editor. 
Sentinel Node Procedure for Breast Cancer: 
training,  safety, reliability and follow-up aspects 
De schildwachtklier procedure voor borstkanker: 
Training, veiligheid, betrouwbaarheid en follow-up. 
Proefschrift
ter verkrijging van de graad van doctor
aan de Erasmus Universiteit Rotterdam 
op gezag van de 
rector magnificus  
Prof.dr. S.W.J. Lamberts
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op  
donderdag 8 juni 2006 om 11.00 uur 
door
Antoinette Yda de Kanter
geboren te Rotterdam
Promotiecommissie
Promotoren:  Prof.dr. A.M.M. Eggermont 
      Prof.dr. T. Wiggers 
Overige leden:   Prof.dr. P.C. Levendag 
      Prof.dr. I.H.M. Borel Rinkes   
      Prof.dr. J.W. Oosterhuis 
To Marcel, 




          
Introduction                                           9 
Chapter 1 Controlled introduction of the sentinel node biopsy in breast cancer         13 
  in a multi-centre setting: the role of a coordinator for quality control.   
Chapter 2 Multicentre study of ultrasonographically guided axillary node biopsy      21 
  in patients with breast cancer. 
Chapter 3 Ultrasound-guided fine needle aspiration cytology of axillary lymph        27 
  nodes in breast cancer patients. A preoperative staging procedure. 
Chapter 4 Non-sentinel lymph node involvement in patients with breast cancer          35 
  and sentinel node micrometastasis; too early to abandon axillary clearance.  
Chapter 5 Reasons for failure to identify positive sentinel nodes in breast cancer         41 
  patients with significant nodal involvement. 
Chapter 6 Radiation protection for the sentinel node procedure in breast cancer.        47 
Chapter 7 Is internal mammary chain sentinel node biopsy worthwhile?           53 
Chapter 8 5-Year follow-up of sentinel node negative breast cancer patients:          67 
  few axillary recurrences, futility of ultrasound of the axilla 
Summary                                 75
Samenvatting                              81
Discussion                               87
Curriculum Vitae                         93






The sentinel node was first described by Cabanas in 1977 describing the first node draining 
the primary tumour in the regional lymphatic basin in penile cancer 1. It took several years 
before Morton et al. described their experience in 1992 with Sentinel Lymph Node Biopsy 
(SLNB) in melanoma 2. Giuliano et al. essentially transferred the same technique of lymphatic 
mapping to breast carcinoma and reported the extensive experience in the John Wayne Cancer 
Center in 1994 3. He described how isosulfan blue was injected in a peritumoral fashion for 
lymphatic mapping. Krag et al. and Meijer et al improved the procedure by introducing a 
radioactive tracer and a hand held probe to detect the radioactive lymph node 4,5. Various 
studies have shown that histopathological examination of the sentinel node is reliable in 
predicting axillary lymph node status in breast cancer. Consequently this procedure can 
replace routine axillary lymphadenectomy when the sentinel node is found to be negative. 
This was demonstrated in a randomized trial by Veronesi et al. 6. The interest in the sentinel 
node concept in breast cancer is enormous because 60% of all patients is found node-negative 
and axillary lymph node dissection is associated with significant morbidity (lymphoedema 
and neuropathy of the involved arm) 7.
Accuracy
 Inspired by promising single institutional results we started a prospective study after the 
value of the sentinel node in operable clinically node negative breast cancer patients. Initially 
there were three participating hospitals: a university hospital, an oncology centre and a 
community hospital. The differences in organisation of the surgery department between these 
hospitals allowed us to compare results and make some recommendations for implementation 
outside academic centres (chapter 1).
Ultrasound of the axilla in combination with fine needle cytology 
 The sentinel node procedure can prevent an unnecessary full lymph node dissection, but is 
for patients with a positive sentinel node an additional surgical procedure, identifying the 
need for a full lymph node dissection. We developed an interest for non-invasive methods that 
can detect positive lymph nodes to reduce the need for sentinel node biopsy. Because of 
promising results that we had demonstrated for ultrasound guided fine needle aspiration 
cytology (US-FNAC) of the clinically node-negative breast cancer patient 8, US-FNAC of the 
axilla had been introduced in our clinic as part of the pre-operative screening of clinically 
node negative breast cancer patients. In case of a positive cytology sentinel node biopsy was 
omitted. In chapter 2 the results of this selection tool will be discussed. Chapter 3 will 
discuss the single institution results of a validation study. 
Micrometastases  
In order to minimize the number of false-negative sentinel nodes, the pathologist examines 
the sentinel node more thoroughly than the large number of lymph nodes in a full lymph node 
dissection. With the examination of several levels and the use of immune histochemical 
staining even the smallest metastases are identified. The necessity of a full axillary lymph 
node dissection in case of diagnosing only a few metastatic cells in the sentinel node is 
questionable and evaluated in chapter 4.
10
Failure
Despite the pre-operative selection tool with ultrasound in combination with fine needle 
cytology and standardization of the procedure false negativity of the sentinel node occurred. 
The search for causes of failure was initiated. Most causes were found to be inherent to the 
implementation of a new procedure. In chapter 5 the phenomenon that extranodal growth 
and/or extensive nodal involvement can block radioactive tracer and patent blue to reach the 
true sentinel node as a cause of false negativity of the sentinel node is discussed. 
Safety
A point of concern was the safety of the procedure. The tracing of the sentinel node 
occurred with the help of a radioactive tracer and a blue dye. The government legislation 
concerning working with radioactive material is very strict and was hampering the 
implementation of the procedure in hospitals without a nuclear department. The exposure to 
radiation was investigated for those involved in the procedure in this study is reported in 
chapter 6.
Internal mammary chain hot-spots 
A point of interest is the meaning of hot-spots of the internal mammary chain (IMC) on 
lymphoscintigraphy. Is this an indication for excision of such an IMC-sentinel node? 9
Despite several studies, up until now there is no national consensus about the clinical 
management. In chapter 7 our long term follow-up results of our patients are described. 
These results could be of help to solve this question. 
Follow-up of sentinel node negative patients and futility of ultrasound 
An other follow-up question is the incidence of axillary lymph node recurrences in SN-
negative patients 10. After our validation study and other national studies the sentinel node 
procedure was implemented in the Netherlands as a safe procedure with an acceptable false 
negative rate. The implementation was started without knowing the late effects, so an 
important question during follow-up is the incidence of axillary recurrences and their 
influence on overall survival. In chapter 8 the 5-year follow-up results of sentinel node 
patients, treated without a full axillary lymph node dissection is discussed. We also evaluated 
the results of ultrasound of the axilla in the follow-up in order to detect recurrences before the 
patient.
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Controlled introduction of the sentinel node biopsy in breast
cancer in a multi-centre setting: the role of a coordinator for
quality control
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Aims: It is proposed that sentinel node biopsy should replace axillary lymph-node dissection. We analysed the role
of a coordinator in the introduction of the sentinel node biopsy in breast cancer in a multi-centre setting to assure
standardization and quality control.
Methods: We included 232 operable breast cancer patients. Part of the procedure was an ultrasound examination of
the axilla with fine needle aspiration cytology. The sentinel node was identified with 99m-Technetium and Patent
Blue.
Results: The results of the procedure, sensitivity and false negativity, were the same for the three participating
hospitals. We think this is mostly due to the coordinator who supplied information about the technique, pitfalls and
results to all teams.
Conclusions: Our experience regarding the organization aspects of introducing the sentinel node procedure in a multi-
centre setting now serves as a model in organizing its application in a much wider number of hospitals.
© 2000 Harcourt Publishers Ltd
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Introduction developed by Morton and others.9–15 Results seem
promising. However, the introduction of the sentinel node
Axillary lymph node dissection (ALND) is still part of the as a standard procedure is still under discussion.16 Before
standard treatment of breast cancer patients for staging the introduction the following requirements should be met:
purposes. There is no evidence that ALND improves local consensus about an acceptable false-negative rate, analysis
tumour control in patients without lymph-node metastases. of causes of false-negative sentinel nodes, a definition of
ALND has many complications; lymphedema, hypesthesia, the role of lymphoscintigraphy and optimization and
stiffness, pain and weakness of the shoulder.1,2 Since SN standardization of all aspects of the procedure. Concern
biopsy has proven to be a reliable predictor of the axillary regarding this new technique and its general use in surgical
lymph-node status it is proposed that SN biopsy should practice has been expressed because in most studies on
replace ALND. sensitivity and accuracy the SN procedure has been
Potential replacement of ALND by imaging techniques performed in a single institution by only one or two
such as computer tomography, ultrasound, SPECT and surgeons.
positron emission tomography has been evaluated in a We studied the sensitivity and accuracy of the SN
number of studies, but as yet none of these methods is procedure in a multi-centre setting. Special attention was
accurate enough to replace ALND, which at this time paid to difficulties in implementation. A study coordinator
remains the gold standard.3–8 was responsible for the quality of the procedure in all three
Sentinel node biopsy is a procedure that could replace participating hospitals. In the first period the coordinator
ALND if sensitivity is as accurate as in an ALND. The SN was responsible for the design of the protocol, instruction
hypothesis was firstly described by Cabanas and further of all involved individuals, and for organizing the interaction
between the departments of Nuclear Medicine, Surgery and
Pathology.During the second periodwe analysed the failuresCorrespondence to: A. Y. de Kanter, C/O Department of Surgical
followed by apposition (if necessary) and continuation ofOncology, University Hospital Rotterdam/Daniel, Groene Hilledijk
301, 3075 EA Rotterdam, The Netherlands. Tel: +31-10-4391506. quality control of the procedure.
0748–7983/00/070652+05 $35.00/0 © 2000 Harcourt Publishers Ltd
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The participating hospitals were: a university hospital in participating hospitals. The study population consisted of
240 women and one man. The diagnosis of the primarywhich every 3 months a new resident performed the
procedure under the guidance of one surgical oncologist (A), tumour was established with mammography, palpation and
cytology. In case of strong clinical suspicion of malignancy,a cancer centre with five surgical oncologists performing the
SN procedure (B) and a general teaching hospital with one a diagnostic and therapeutic lumpectomy was performed
before SN biopsy (n=71). No frozen sections of theexperienced surgeon responsible for the SN procedure (CC).
We report here on the results obtained in this setting and lumpectomy were performed because of proper pathological
diagnosis and to avoid SN/ALND in DCIS patients.the role of the coordinator in standardizing procedures in
the different hospitals and assuring quality control. Patients with palpable nodes, necessity for neoadjuvant
chemotherapy or multifocal tumours were excluded (n=9).
Role of the coordinator The remaining 232 patients were included. Part of the
sentinel node procedure was an ultrasound of the axillaThe role of the coordinator was two-fold; firstly the
with fine needle aspiration cytology (FNAC). If cytologysupervision of the implementation of the procedure, and
showed tumour cells, these patients were scheduled forsecondly to refine the procedure upon the collected data.
ALND. If cytology was negative, patients were scheduledWe started with a procedure based upon data in the
for SN biopsy. Informed consent for the sentinel nodeliterature. The sentinel node tracing-technique was mainly
biopsy was obtained from all. Identification of the SN wasself-made and refined by visiting one of the few sentinel
performed with 30–40 MBq 99m-Technetium nano-node performing hospitals.
colloid (Solconanocoll®) injected subcutaneously andEligibility of all patients with proven breast cancer was
peritumorally at least two and a half hours before operation.checked by the study coordinator. Informed consent about
In cases of a preceding lumpectomy the radioactivity wasthe sentinel node procedure was obtained by the surgeon
injected cranially of the scar in healthy breast tissue. If theand, if necessary, the coordinator was asked to explain more
operation was planned for the next day the amount ofabout the procedure to the patient.
tracer was doubled (n=12). Two hours post-injection aAll nuclear departments were instructed to use the same
lymphoscintigraphy was made in anterior, anterior–obliquedose radioactive tracer and material. If possible the
and lateral views. For logistic reasons no scan was made incoordinator injected the 99m-Technetium-nanocolloid
23 patients. Visible nodes were traced with a cobalt stickherself and while injecting instructed others how to
and marked on the patients’ skin with a felt pen. At thedetermine the injection sites and possible pitfalls. To create
beginning of the operation 0.5 ml Patent Blue was injecteda standard procedure we performed a 1-day procedure if
intradermally above the tumour, or in cases of a precedingpossible. For a 1-day procedure the intervals between
lumpectomy cranially of the scar. Subsequently the SN wasinjection and lymphoscintigraphy were 2 hours, and between
identified with guidance of a RMD-CTC4 or C-trac probelymphoscintigraphy and operation less than 6 hours.
and the blue-stained lymph vessel. For the first 10 patientsAll lymphoscintigraphy scans were performed in the same
in the study the sentinel node was traced in the specimenposition. All scans were reviewed by the coordinator and
after resection of the axillary lymph nodes. Later on weexplained by the surgeons. If there was a mark on the
identified and removed the sentinel node first before apatient’s skin there was an explanation written regarding
complete ALND was performed. All axillary specimenswhich node was marked and which scanning direction was
were processed for histological examination usingused.
haematoxylin and eosin (H&E) staining. The SN(s) wereIf possible the coordinator was present at each procedure.
examined with multiple sections (four to eight) andAll surgeons were instructed to inject the blue dye in the
immunohistochemical staining (IHC) using cytokeratinesame dose and place with regard to the tumour and to use
antibody (CAM 5.2) in order to improve the detection ofthe same approach. This approach was developed in the
(micro) metastases.first few weeks of the study and during regular meetings
problems were solved and standardized.
Information about the technique and pitfalls/results were
Resultscontinuously supplied to all teams by the coordinator.
Another important task of the coordinator was to instruct
We enrolled 232 patients in this study, 63 in the universitythe surgeon how to use the probe, in particular the direction
hospital, 107 in the cancer centre and 62 in the municipalof scanning was a pitfall (in one line towards the sites of
hospital. Table 1 shows the characteristics of the procedure.injection). The operation theatre personnel were instructed
Ultrasound examination and FNAC diagnosed metastasesabout the essential functions of the probe and how to handle
in 33 patients (16% of all breast cancer patients examinedit. Uneasiness about the radioactivity of the breast, sentinel
with U.S., 35% of all node positive patients).node and swabs was reduced in cooperationwith the division
In 69% the tumour in the breast was discovered byof radiation protection.
physical examination. The localization of the tumour in theAfter the instruction and teaching period the coordinator
lateral quadrant was about 50%. The surgery performedwas in charge of controlling the quality of the procedure.
was modified radical mastectomy (40%), modified radical
mastectomy after diagnostic lumpectomy (17%),Patients and methods
lumpectomy and ALND (29%), or ALND alone after
diagnostic lumpectomy (14%). In 88% of the patients theFrom December 1996 till November 1998, 241 consecutive
patients with operable breast cancer visited one of the three operation was on the same day as the injection of the
Controlled introduction of the sentinel node biopsy 
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Table 1. Characteristics of the SN procedure
University Cancer centre General Total
No. of surgeons 6 5 1 12
No. of patients 63 107 62 232
Positive FNAB primary tumour 10 17 6 33
% after lumpectomy 19% 36% 32% 31%
% 1 day procedure 87% 97% 79% 89%
Probe RMD RMD C-trac
Amount of radioactivity 40 MBq 30 MBq 30 MBq
Table 2. Characteristics of the patients
University Cancer centre General Total
%SN positive scan 100% 85% 89% 89%
No. of parasternal SNs 6 5 3 14
% [1 identified SN 92.5% 91.6% 95.2% 92.5%
% [1 SN with lump 95% 94% 100% 96%
Mean no. of SNs 1.6 1.3 1.5 1.5
% N+ T1a+b:T1c:T2:T3 22%:29%:57%:100% 22%:30%:58%:100% 22%:38%:53%:100% 22%:31%:56%:100%
No. of false negative SNs 2 2 1 5
radioactive tracer. The mean time between injection and
operation was 4.5 hours (1.5–7). In the patients who
underwent surgery the next day the mean time between
injection and operation was 19 hours (15–26).
Table 2 summarizes the characteristics of the patients
treated in the participating hospitals. In this table the
heterogeneity of the patient groups and hospitals is
indicated.
Lymphoscintigraphy identified one or more hot spots in
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a hot-spot parasternally besides axillary activity. We tried
to localize and remove this hot spot in two patients; in one Fig. 1. The learning curve of the sentinel node. The detection rate
patient this procedure was associated with bleeding. In the calculated over the preceding 25 patients.
other 12 patients no attempt was made to remove the
parasternal nodes.
In 15 patients no SN could be identified either by
radioactive tracer or by blue dye. In 10 of these patients a
diagnostic lumpectomy was performed a few weeks before
SN biopsy. These 15 patients were distributed equally among


































































preceding lumpectomy) occurred in the first year of the
study. After more careful palpation of the lumpectomy Fig. 2. Pathological and statistical results.
cavity and placing the radioactive depots 1–1.5 cm outside
this area in normal breast tissue there was no difference in radioactive and blue in 77%, only radioactive in 18% and
only blue in 4%. In one patient the SN, blue only, wasidentification rate between patients after lumpectomy or
with tumour in situ. However, in most patients with a found to be falsely negative. Histological examination of
the SN with multiple sections and H&E staining identifiedpreceding lumpectomy no metastases were found on
histological examination, so there is no absolute assurance metastases in 52 patients. IHC found a (micro)metastasis
in an additional eight patients. The SN was negative in 124that the correct SN was identified and removed. The average
number of retrieved lymph nodes was 14.6 (5–37). The mean patients, but in five of them a metastasis was found in one
of the non-sentinel LN. In 32 patients the SN was the onlynumber of sentinel nodes was 1.5 (0–3). In Fig. 1 the
traceability of the SN is shown calculated as the results of positive node.
The sensitivity of the procedure (ultrasound and sentinelthe last 25 patients. The first 10 patients of the study were
left out because the SN was detected in the ALND specimen node) defined as the percentage of a correct prediction of
the axilla in node positive patients is 95%, with an accuracyoutside the patient. There was a learning curve of less than
50 patients in our study. of 97.7%. For the participating hospitals A, B and C the
sensitivity is 93.3%, 95.1% and 96.7%, respectively (Fig. 2).The identified SN, traced with both methods, was
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Discussion inexperienced surgeons. The greatest concern is quality
control during and after the learning period. As mentioned
earlier, one person who observed almost every SN biopsyRecently, considerations were discussed as to whether or
not the sentinel node should be introduced as the standard and reported experiences and pitfalls of surgeons
coordinated our study, and we think this greatly influencedtreatment; it was concluded that the time is not yet ready.16
The first argument is that a SN biopsy must be proved the results. However, this influence can not be calculated
precisely. In our region the introduction of the SN procedureto be as accurate as full ALND or it must be decided that
a less accurate staging procedure will be acceptable because will be centrally coordinated as recommended by the
aforementioned study group. Our experience regarding theof its low morbidity. These arguments can be met if losses
and gains of the new procedure can be calculated. Serial organizational aspects of introducing the sentinel node
procedure in a multi-centre setting now serves as a modelsectioning and immunohistochemical staining will increase
the number of positive lymph nodes17–19 and false-negative to organize its application in a much wider number of
hospitals. In the first period of introduction there will beoutcomes will reduce the profit. Comparison of the two
numbers will show the overall loss or gain of the procedure. one coordinator visiting all regional hospitals (23 hospitals,
1200 patients with breast cancer yearly) and develop theIn our study the additional profit of the multiple sectioning
is not known but the IHC reveals metastases in an additional optimal procedure for each hospital. After that period there
will be meetings analysing reasons to learn from mistakes7%, the loss is 5% so there is an overall profit of at least
2%. made. Because there are no studies with a follow-up of 5
or more years of the node-negative patients treated with aIn the Netherlands a multi-disciplinary group consisting
of surgeons, pathologists and nuclear medicine specialists SN biopsy, we will also regionally register all patients
undergoing an SN biopsy. After the learning curve thewas installed to coordinate the introduction of the SN
procedure in the Netherlands.20 It was suggested that a breast cancer patients will be treated with removal of the
tumour and a sentinel node biopsy. The axilla of SN negativefalse-negative rate of 5% is acceptable provided that the
profit of multiple sectioning and IHC will exceed this rate. patients will be examined by an ultrasound once a year in
order to control the axillary lymph nodes left behind. WithThe 5% false-negative rate results in the following
calculation; 95% positive predictive value, the sentinel node this examination we hope to maintain the present high level
of local control.in 19 of 20 patients with lymph node metastases predicts
the axillary status correct. A metastases rate of 40% After many publications regarding the value of the
sentinel node procedure in breast cancer patients, all withcombined with a positive predictive value of 95% results in
(at least) 50 SN ‘double’ procedures (a combined procedure positive results, we conclude that there is no doubt about
the SN concept for breast cancer; the SN is as accurate asof both the SN procedure and a full ALND).
A suggestion was made to determine such an acceptable a staging procedure as a complete ALND. Based on our
experience we recommend a double procedurepercentage for every T-subgroup. To do so, very large
subgroups are needed, especially in T1a and b, because the (SN+ALND) during the learning curve of 50 patients. If
the above standard of less than 5% false-negative results israte of lymph-node positive patients is low. The T1a and b
patients are exactly those who would benefit from a correct met, a hospital can proceed with SN biopsy only, provided
that there is a central registration point and adequate follow-staging of the axilla, the false-negative rate should be as
low as possible. However, one false-negative rate for all up. Regular ultrasound of the axilla during follow-up is
recommended.21patients is reported in all studies. Another problem is that
the pT is not 100% in concordance with the cT.
An important point is the lack of a standard procedure.
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World Wide Web Site Reviews
In order to help and to encourage our readers to make the best use of the cancer related and surgical oncology
resources on the Internet, we are pleased to offer to publish short Web Site Reviews in the Highwayman series. A
review may address any site in the broad subject range of our remit or in relation to our recently published articles.
The site under review might be a search engine; an information or reference source, of historical or biogeographical
interest; a cancer charity; a grant giving body; a complementary or alternative medicine source; or offbeat.
Kim et al. have recently published a series of criteria for evaluating health related web sites, which provide a useful
framework for would be reviewers. They include:
—the content of the site, including quality, reliability, accuracy, scope and depth;
—design and aesthetics, layout, interactivity, presentation, appeal, graphics and use of media;
—disclosure of authors, sponsors and developers;
—currency of information and maintenance of the site;
—the authority of the source;
—the ease of use, including facility to download, navigability and functionality;
—quality of links to other sites;
—attribution and documentation;
—appropriateness for intended audience;
—contact addresses and feedback mechanisms;
—user support;
—unique features.
Reviews should be between 200 and 500 words, and without illustrations or screen snapshots. They may be
submitted for publication either as signed reviews or anonymously under the ‘Highwayman’ imprint. They offer a
particular opportunity for your trainees and younger web wizards to exercise their pens and keyboards in creative
writing.
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Abstract
Currently, axillary lymph node dissection is increasingly being replaced by the sentinel node procedure. This method is time-
consuming and the full immunohistochemical evaluation is usually only first known postoperatively. This study was designed to
evaluate the accuracy of preoperative ultrasound-guided fine needle aspirations (FNAs) for the detection of non-palpable lymph
node metastases in primary breast cancer patients. We evaluated the material of 183 ultrasound-guided FNAs of non-palpable
axillary lymph nodes of primary breast cancer patients. The cytological results were compared with the final histological diagnosis.
Ultrasound-guided FNA detected metastases in 44% (37/85) of histologically node-positive patients, in 20% of the total patient
population studied. These pecentages are likely to be higher when women with palpable nodes are included. Cytologically false-
negative and false-positive nodes were seen in 28 (15%) and three cases (1.6%), respectively. Interestingly 25% (n=7) of the false-
negative nodes, revealed micrometastases on postoperative histology. The sensitivity was 57%, the specificity 96%. We conclude
that ultrasound-guided FNA of the axillary lymph nodes is an effective procedure that should be included in the preoperative sta-
ging of all primary breast cancer patients. Whether lymph nodes are palpable or not, it will save considerable operating time by
selecting those who need a complete axillary lymph node dissection at primary surgery and would save a significant number of
sentinel lymph node dissections (SLNDs).
# 2002 Elsevier Science Ltd. All rights reserved.
Keywords: Breast cancer; Ultrasound; FNA; Lymph node; Axilla
1. Introduction
Lymph node status has long been the golden standard
in determining the prognosis of breast cancer patients.
Lately, the need for complete axillary dissection as a
common staging procedure for all breast cancer patients
has been questioned, because of the high morbidity of
the procedure caused by lymphoedema and neuropathy
of the involved arm. For this reason, regional lymph
node staging by histological examination of the so-
called sentinel node, defined as the first node draining
the primary tumour in the regional lymphatic basin, has
been introduced. Various studies [1–3] have now shown
that histopathological examination of the sentinel node
is reliable in predicting axillary lymph node status in
breast cancer. Consequently, this procedure can replace
routine axillary lymphadenectomy when the sentinel
node is found to be negative. However, the procedure is
time-consuming and the full histological and immuno-
histochemical evaluation is often only first known post-
operatively. It would therefore be of great interest for
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the patient and surgeon to find an accurate technique
for identifying lymph node metastases preoperatively.
Bonnema and colleagues [4] have studied the accuracy
of ultrasonographically-guided fine needle aspiration
(FNA) of non-palpable axillary lymph nodes in detect-
ing breast cancer metastases. They found that ultra-
sound-guided FNA of the axilla could be performed in
62% of patients with primary breast cancer and that
63% of all node-positive patients could be detected pre-
operatively by this method. In a multicentre study of the
sentinel node staging procedure, the preoperatively per-
formed ultrasound-guided cytology showed a 36%
detection rate of the lymph node metastases [5]. These
results were promising and in our institute FNA cytol-
ogy of non-palpable axillary lymph node under ultra-
sound guidance before primary surgery has become the
standard procedure in the preoperative staging of pri-
mary breast cancer patients. Here, we present the out-
come of our analysis of the cytology of axillary lymph
nodes of breast cancer patients collected between Jan-
uary 1998 and July 2000.
2. Patients and methods
2.1. Patient material
Axillary lymph node material from 180 patients with
a primary diagnosis of breast cancer was collected from
January 1998 until July 2000. 3 patients had bilateral
breast carcinomas and therefore FNAs of both left and
right axillary nodes were performed. Thus, the final
study consisted of material from 183 lymph nodes of
180 patients. Ultrasonographic evaluation of the axilla
was carried out with an Acuson XP 128 (Acuson,
Mountain View, CA, USA) using a 7.5-MHz linear
array transducer. When lymph nodes were visible an
ultrasound-guided FNA was performed with a 21-G
needle, regardless of the benign/malignant ultrasound
pattern. When more nodes were seen, either the sono-
graphically most malignant looking, or the one closest
to the breast and therefore most likely to be the sentinel
node, was aspirated. The slides were Giemsa stained
and evaluated according to the following three criteria:
none or only few lymphocytes: inadequate; many lym-
phocytes, but no epithelial cells: benign; atypical epi-
thelial cells in combination with lymphocytes:
malignant. When atypical epithelial cells, but no lym-
phocytes were found and it was not apparent that an
actual lymph node was aspirated, it was mentioned in
the conclusion.
When the cytological diagnosis of the lymph node was
positive, a complete axillary lymph node dissection was
performed at primary surgery. In all other cases, a rou-
tine sentinel node procedure was applied as described in
Ref. [5]. In short, the identification of the sentinel node
was realised by peritumoral injection of 30–40
MBq99mTc-radiolabelled nanocolloid at least 2.5 h
before surgery and intradermal injection of 0.5 ml
patent blue dye during the operation. The sentinel node
was identified with the guidance of the RMD-CTC4
probe (Radiation Monitoring Devices, Watertown, ME,
USA) and the blue- stained lymph vessel. Frozen sec-
tions of the sentinel node were examined and when
negative, multiple at 250-m intervals stepwise, sectioned
paraffin slides were studied—following standard histo-
logical and immunohistochemical staining procedures
using a monoclonal antibody against low molecular
weight cytokeratin (CAM 5.2, Dako, Denmark) [6].
Histological features of the tumour were recorded.
Typing was performed following the World Health
Organization (WHO) classification, grading was done
according to Bloom and Richardson [7].
The results were analysed with descriptive statistical
methods. Sensitivity, specificity, overall accuracy, and
positive and negative predictive values were calculated
by comparing the results of FNAB and histological
findings.
3. Results
The clinicopathological features of the primary breast
cancers are listed in Table 1. The histological subtypes
included 155 ductal, 12 lobular, 5 mixed and 11 other
type carcinomas. Most tumours were grade II (n=77,
42%), pT1 (n=131, 72%) and N0 (n=98, 54%). There
was only one pT3 tumour.
Table 2 gives the correlation between the cytological
and histological diagnosis of the axillary nodes. In
Table 1
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49/183 (27%) cases, insufficient material was aspirated,
20 of which were histologically-positive. In 103/183
(56%), the cytology and histology was concordant, i.e.
37/103 were both positive for malignancy and 66/103
were both negative for malignancy. In 31/183 (17%)
lymph nodes, the cytological and histological results did
not correspond: in 28 cytologically-negative cases, his-
tologically-positive lymph nodes were seen. However,
histology of three cytologically-positive nodes (1.6%)
did not reveal cancer metastases. Reviewing the cytol-
ogy of the latter lymph nodes, we found that the mate-
rial presented as lymph node aspiration in one case did
show tumour cells against a background of lymphocytes
and was in our opinion therefore rightly considered to
be a metastasis. However, histology showed that the
primary tumour was multifocal and the more laterally
located small tumour area in particular was surrounded
by lymphocytes. This lateral tumour extension was
considered a likely explanation for the positive cytology
result. In the next case at second look, the aspirated cell
groups, misread as metastatic groups, were interpreted
as mesothelial cells. Apparently, the radiologist had
aspirated material from the pleural cavity. In the last
case, tumour groups but no lymphocytes were seen in
the cytological specimen, but since the consulted radi-
ologist confirmed that an axillary lesion was aspirated,
it was considered to be a lymph node metastasis.
Nevertheless, no positive nodes were found in the sur-
gical specimen.
Most inadequate and false-negative aspirations were
found in the group with one positive node, 13 and 17,
respectively (Table 3). Of these 17 false-negative aspira-
tions, seven contained micrometastases only, i.e. 25%
(7/28) of the total number of cytologically false-negative
nodes.
Of the total group with one histologically-positive
node, 25% was cytologically-detected, compared with
83% in the group with more than three positive nodes.
Three patients with a positive sentinel node refused fur-
ther surgery and, consequently, no axillary dissection
was performed and the number of positive nodes is
unknown. In those cases, regular ultrasound exami-
nations of the axilla were included in the follow-up.
The relationship between the size of the tumour, the
number of histologically-positive nodes and cytological
detection, is shown in Table 4. In 29% (14/49) of T1
tumours and and in 64% (23/36) of T2 tumours histo-
logically-positive nodes were cytologically-detected, in
57% (13/23) of T2 tumours with more than three posi-
tive nodes.
In 20% of the total patient population studied, lymph
node metastases were cytologically-detected. This is
44% (37/85) of the group of patients with histologically-
proven positive lymph nodes.
The sensitivity (the aspirations with inadequate mate-
rial not included) was 57%, the specificity 96%, overall
accuracy 76% and positive and negative predictive
values 92%, and 70%, respectively.
4. Discussion
A simple reliable preoperative assessment of the axil-
lary lymph node status of primary breast cancer patients
would be of great value for the patient and surgeon,
especially since the introduction of the sentinel node
procedure. It would save time and costs by avoiding this
procedure when metastases are found. Non-palpable
axillary lymph nodes can be detected by ultrasound.
Unfortunately, the accuracy of ultrasonography is too
low to rely on this technique for the selection of
Table 2
Correlation between cytological and histological diagnoses
Cytology Histology
n Benign Malignant
Inadequate 49 29 20
Benign 94 66 28
Malignant 40 3 37
Total 183 98 85
Table 3
Correlation between cytological diagnosis and lymph node status
Number of histologically-positive lymph nodes
Cyt n=1 n=2–3 n=>3 Unknown Total (%)
Inadequate 13 (5a) 4 1 2 (1a) 20 (24)
Benign 17 (7a) 7 3 1 28 (33)
Malignant 10 7 20 – 37 (44)
Total 40 18 24 3 85
a Number of lymph nodes with only micrometastases.
Table 4
Correlation between tumour size and number of histologically-positive
lymph nodes (number of cytologically-detected nodes between par-
entheses)
N=1 N=2–3 N=>3 N? Total (%)
T1
1a 1 – 1 – 2
1b 8 (1) 1 (1) – – 9 (2)
1c 20 (3) 7 (2) 9 (7) 2a 38 (12)
T2 11 (6) 10 (4) 14 (13) 1a 36 (23)
Total 40 (10) 18 (7) 24 (20) 3 85 (37)
a 3 patients with a positive sentinel node, refused further surgery
and therefore the number of positive nodes is not known.
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node-negative/positive patients, the sensitivity being 36–
73% and the specificity between 70 and 100% [4,5,8–
10]. A combined approach of ultrasound and FNA
cytology is rarely applied [4,5,11], but the results are
promising. Bonnema and colleagues [4] found that in
87% of ultrasound-guided FNA of axillary lymph
nodes, adequate material was aspirated, with a sensitiv-
ity and specificity of 63 and 100%, respectively. In the
study of Kanter and colleagues [5], the sensitivity was
36% and the specificity 100%. We found that 73% of
lymph node aspirations contained adequate material
with a sensitivity of 57% and a specificity of 96%. These
variations in the detection of metastases may be
explained by the fact that in Bonnema’s study two
experienced radiologists were involved whereas in the
other two studies, several radiologists did the aspira-
tions and some of them had little experience with this
technique. However, after a learning phase, the identifi-
cation and aspiration of lymph nodes improved and so
did the results (data not shown). It underlines the
importance of good communication between the radi-
ologist, pathologist and surgeon to maintain high stan-
dards with regard to the quality of the proceedings.
Unfortunately, 3 cases of positive cytology proved to
be negative in histology. In 1 case this could be
explained by the multifocality of the tumour, associated
with a dense lymphocytic infiltrate. It is known that in
multifocal breast cancer, a negative sentinel node does
not exclude axillary metastases [12]. Therefore, a com-
plete axillary lymph node dissection has to be per-
formed. The second false-positive case was caused by
cytological misreading of the cell groups. Here, a com-
plete lymph node dissection was an overtreatment.
Awareness of the rare possibility that the pleural cavity
is aspirated may help to avoid this pitfall. The third case
remains unexplained.
Cytologically false-negative and inadequate findings
were in general restricted to the group of patients with
one or 2–3 positive nodes. That so few lymph nodes are
positive may explain why aspiration is more difficult
and the chance of sampling errors is enhanced. What is
even more important, 25% of the cytologically false-
negative lymph nodes, were found histologically to
contain micrometastases only. Although the biological
significance of these micrometastases is still being dis-
cussed, it is clear that neither ultrasound nor cytology
can replace histology in the detection of these metas-
tases, but it partly explains the relative low sensitivity
(57%) found in this study.
Screening programmes have led to an earlier diag-
nosis of breast cancer and therefore smaller invasive
cancers [13]. Moreover, the size of the tumour is related
to the number of nodes involved [14–16]. Consistent
with these findings, we observed that 131/183 (72%) of
the tumours were T1. However, the percentage of T1
tumours with positive nodes was relatively high (37%)
compared with other studies [16–18]. Most likely a
selection bias has occurred. After all, patients were
selected upon the sonographical visibility of the axillary
lymph nodes and since metastic lymph nodes are in
principal visible, the chance of nodes being positive was
much higher in this group than in a population of pri-
mary breast cancer patients with no visible nodes.
In this study, ultrasound-guided FNA could identify
44% of histologically-proven axillary metastases in pri-
mary breast cancer patients with pT1 and pT2 tumours,
20% of the total patient population. Consequently, the
sentinel node procedure could be avoided, saving con-
siderable operating time as the surgeon can proceed to
axillary dissection without waiting for frozen sections
and avoiding a second operation later.
Both ultrasound and FNA are non-aggressive,
patient-friendly and reliable methods, relatively easy to
apply when in experienced hands. We conclude that
ultrasound-guided FNA of the axilla should be included
in the preoperative staging procedure of all primary
breast cancer patients. It it will save a significant num-
ber of SLNDs, by selecting those patients who need a
total axillary lymph node dissection at primary surgery.
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ORIGINAL ARTICLE
Non-sentinel lymph node involvement in patients with
breast cancer and sentinel node micrometastasis; too
early to abandon axillary clearance
M A den Bakker, A van Weeszenberg, A Y de Kanter, F H Beverdam, C Pritchard,
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J Clin Pathol 2002;55:932–935
Aims: It has been suggested that patients with T1–2 breast tumours and sentinel node (SLN) microme-
tastases, defined as foci of tumour cells smaller than 2 mm, may be spared completion axillary lymph
node dissection because of the low incidence of further metastatic disease. To gain insight into the
extent of non-sentinel lymph node (n-SLN) involvement, SLNs and complementary axillary clearance
specimens in patients with SLN micrometastases were examined.
Methods: A set of 32 patients with SLN micrometastases was selected on the basis of pathology
reports and review of SLNs. Five hundred and thirteen n-SLNs from the axillary clearance specimens
were serially sectioned and analysed by means of immunohistochemistry for metastatic disease. Lymph
node metastases were grouped as macrometastases (> 2 mm), and micrometastases (< 2 mm), and
further subdivided as isolated tumour cells (ITCs) or clusters.
Results: In 11 of 32 patients, one or more n-SLN was involved. Grade 3 tumours and tumours > 2 cm
(T2–3 v T1) were significantly associated with n-SLN micrometastases as clusters (grade: odds ratio
(OR), 8.3; 95% confidence interval (CI), 1.4 to 50.0; size: T2–3 tumours v T1: OR, 15; 95% CI, 2.18
to 103.0). However, no subgroup of tumours with regard to size and grade was identified that did not
have n-SLN metastases.
Conclusions: In patients with breast cancer and SLN micrometastases, n-SLN involvement is relatively
common. The incidence of metastatic clusters in n-SLN is greatly increased in patients with T2–3
tumours and grade 3 tumours. Therefore, axillary lymph node dissection is especially warranted in
these patients. However, because n-SLN metastases also occur in T1 and low grade tumours, even
these should be subjected to routine axillary dissection to achieve local control.
The sentinel node procedure was pioneered for penilecarcinoma.1 In recent years, it has been introduced forbreast cancer, where its main purpose is to gain insight
into the status of the axillary basin for the presence of meta-
static disease.2 3 Axillary clearance with its associated morbid-
ity can be avoided if metastatic disease in the SLN cannot be
proved. To rely on the SLN procedure in guiding patient man-
agement, it is essential that it be thoroughly investigated.
Many studies have clearly shown that more sensitive
techniques such as serial sectioning, the use of immunohisto-
chemistry, and molecular techniques (such as reverse tran-
scription polymerase chain reaction) dramatically increase the
detection rate of metastatic disease in lymph nodes.4–10 A direct
consequence of this enhanced sensitivity is the observed
increased incidence of micrometastatic and “occult” disease.
Although not all studies agree on this, several papers showed
a survival disadvantage for patients with micrometastatic
disease.6 11–13
In addition to its application as a staging procedure in guid-
ing further treatment, it has been suggested that the SLN pro-
cedure may in certain circumstances serve a secondary func-
tion as ameans of local disease control by removingmetastatic
disease.14 15 In this setting, it is assumed that the SLN has
effectively filtered out early metastatic disease before tumour
microemboli have had the chance to spread beyond the initial
lymph node. Furthermore, it is assumed by some that certain
forms of micrometastatic disease, such as isolated tumour
cells, may not have the potential for outgrowth.4 16 Accepting
these hypotheses implies that metastatic disease in n-SLNs
should only rarely be found in cases with SLN micrometas-
tases. To test these assumptions we examined the n-SLNs of
patients with micrometastatic SLN disease.
“It has been suggested that the sentinel lymph node pro-
cedure may in certain circumstances serve a secondary
function as a means of local disease control by removing
metastatic disease”
METHODS
Identification of the sentinel node was performed by
peritumoral injection of 40 MBq (99m)Tc radiolabelled nano-
colloid at least 2.5 hours before surgery and intradermal
injection of 0.5 ml patent blue dye during surgery. The sentinel
node was identified with the guidance of the RMD-CTC4
probe (Radiation Monitoring Devices, Watertown, Maine,
USA), aided by visual identification of the blue stained vessel,
and was removed under general anaesthesia. After frozen sec-
tion analysis (superficial level of one half of a bisected lymph
node), the remaining SLN tissue was formalin fixed and par-
affin wax embedded. Large nodes were trimmed down into
smaller pieces and submitted in toto for histology. Sections
were cut at four 250 µm intervals with parallel haematoxylin
and eosin (H&E) and immunohistochemical (IHC) staining
with anticytokeratin antibodies.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abbreviations: CI, confidence interval; H&E, haematoxylin and eosin;
IHC, immunohistochemistry; ITC, isolated tumour cell; LN, lymph node;
n-SLN, non-sentinel lymph node; OR, odds ratio; SLN, sentinel lymph
node
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On the basis of pathology reports, 40 patients were
identified who had an SLN micrometastasis. The SLNs and
primary tumours of these patients were reviewed. Grading of
the primary tumours was performed according to the
modified Bloom and Richardson criteria.17 The sizes of the SLN
and n-SLN micrometastases were measured on the micro-
scope stage using the Vernier scale; in equivocal cases, a digital
image was acquired and measurements were made using an
image analysis application (AutoCyte Link; TriPath Imaging
Inc, Burlington, North Carolina, USA). Metastases were
divided into three groups, namely: metastases larger than
2 mm (macrometastases); micrometastases (< 2 mm) con-
sisting of groups of four or more cells in close approximation,
termed clusters; and micrometastases consisting of isolated
single tumour cells or small collections of up to three tumour
cells together, designated as isolated tumour cells (ITCs).16
Whenmultiple micrometastases were present in a single node,
the largest metastasis was measured. The sizes of individual
metastases were not added together. After reviewing the
SLNs, eight patients were excluded from our study (in seven
patients the metastasis was over 2 mm in size, one patient did
not proceed to axillary node dissection). The remaining 32
patients formed the basis of our study. From these patients, all
n-SLNs were cut at 250 µm intervals through the paraffin wax
block, resulting in three to 10 additional sections for each
block. The sections were immunostained with anticytokeratin
antibody CAM 5.2 (Becton Dickinson, Mountain View,
California, USA) using a standard peroxidase–anti-peroxidase
procedure in an automated immunostainer (Mark V; DPC, Los
Angeles, California, USA). Appropriate positive and negative
controls were incorporated in each run of the immunostainer.
In equivocal cases, H&E stained sections were prepared from
retained ribbons for comparison. The presence of micrometas-
tases was scored and compared with the tumour parameters
size and grade using the statistical package SPSS for Windows
release 10.05 (SPSS Inc, Chicago, Illinois, USA).
RESULTS
Thirty two patients with breast cancer were identified with a
SLN micrometastasis. Forty five SLNs were derived from these
patients, ranging from one to four lymph nodes (LNs)/patient
(median, one). The primary tumours were 27 ductal type
adenocarcinomas “not otherwise specified” and five lobular
carcinomas (table 1). Mean tumour size was 19 mm (range,
6–55 mm). The axillary clearances yielded 513 LNs (range,
3–28; median, 14). Because of the poor clinical condition of
one patient, only a limited (level 1) LN dissection was
performed, yielding four LNs. Metastases in n-SLNs were
identified in 24 of 513 LNs (4.7%) from the axilla of 11 of 32
patients, five of whom had initially been diagnosed as not
having n-SLN metastases (“occult metastases”) (table 2). In
addition to eight identified involved n-SLNs in the original
reports, 16 extra involved n-SLNs were documented after
serial sectioning and IHC. In two patients a macrometastasis
was found. Three patients had ITCs only, two patients only had
clusters (including one patient with a macrometastasis), and
six patients had ITCs and clusters (including one patient with
a macrometastasis). The number of involved n-SLNs ranged
from one to four (median, two). Within the group of 11
patients with n-SLN micrometastases, 10 carcinomas were of
the ductal type and the 11th case was a lobular carcinoma. The
mean tumour size in this group was 26.1 mm (range, 12–55).
Two of the carcinomas in this group were multifocal (multiple
non-continuous foci of invasive carcinoma, not necessarily
confined to one quadrant). In the group of 21 patients without
n-SLN micrometastases, the mean tumour size was 14.7 mm
(range, 6–35), 17 carcinomas were of the ductal type and four
tumours were lobular carcinomas. In this group of patients,
two patients had only ITCs in the SLN, two patients had ITCs
and clusters, and the remaining 17 patients had clusters.
The average tumour size was significantly larger in patients
with involved n-SLNs than in those without n-SLNmetastases
(26.1 mm (SD, 14.3) v 14.7 mm (SD, 7.2); t test, t = 2.474
(unequal variance); p = 0.028). The presence and type of
metastasis (ITC v cluster) of n-SLN metastases was analysed
with respect to tumour size and grade by calculating relative
odds (odds ratio; OR). A significantly greater risk of positive
n-SLNs with clusters was found for high grade tumours (OR,
8.3; 95% confidence interval (CI), 1. 4 to 50.0). The odds of
n-SLN metastases as clusters were significantly greater for
carcinomas > 2 cm (OR, 15; 95% CI, 2.18 to 103.0).
Table 1 Tumour characteristics of patient set
Positive n-SLN Negative n-SLN












n-SLN, non-sentinel lymph node.
Table 2 Characteristics of tumours and results in 11 patients with n-SLN involvement











1 2 (SLN1 and SLN2 ITC) 19 ITC+ cluster (4)‡ Ductal 25 3
2 2 (SLN1 ITC+ cluster, SLN2−) 13 ITC (1) Lobular 50 1
3 1 (cluster) 8 Cluster* (3)‡ Ductal 12 1
4 1 (cluster) 22 Cluster (1) Ductal 21 3
5 1 (cluster) 10 ITC (1)‡ Ductal 17 2
6 1 (cluster) 11 Cluster* (2) Ductal 26 2
7 1 (cluster) 15 Cluster† + ITC (4) Ductal 30 3
8 3 (SLN1 cluster, SLN2 and SLN3−) 4 Cluster (2) Ductal 20 3
9 1 (cluster) 22 Cluster† (3) Ductal 21 2
10 1 (cluster) 10 ITC (1)‡ Ductal 55 2
11 1 (ITC+ cluster) 28 Cluster (2)‡ Ductal 10 3
*n-SLN micrometastasis larger than SLN metastasis; †n-SLN macrometastasis; ‡negative n-SLN status in
original report.
B&R, Bloom and Richardson; ITC, isolated tumour cell; nSLN, non-sentinel lymph node; SLN, sentinel lymph
node.
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DISCUSSION
The question arises whether the presence of microscopic
tumour deposits in the SLN justifies complete axillary
clearance and adjuvant treatment. It may be argued that for
staging purposes the object has been achieved by finding
metastatic disease in the SLN and that further involved nodes
are unlikely to be found.Moreover, the viewmay be taken that
removing an SLN with micrometastatic disease constitutes
adequate local control and that axillary clearance is not justi-
fied in these cases. Accepting this perspective implies that
either metastatic deposits in n-SLNs are highly unlikely or
that even if further micrometastatic deposits in n-SLNs are
present these will not result in locoregional disease.
To gain insight into possible metastatic disease in the
remaining (non-sentinel) axillary LNs we performed serial
sectioning with IHC on the n-SLNs of 32 patients with SLN
micrometastases. Metastases were grouped as macrometas-
tases (> 2 mm) and as micrometastases (< 2 mm).Microme-
tastases were further subdivided into “clusters” (four or more
cells together) and isolated tumour cells (single cells and
groups of up to three cells together).We found that in 11 of 32
patients metastatic disease was present in non-sentinel nodes
from the axilla, whereas in seven patients more than one node
was involved and in four patients the n-SLN metastasis was
larger than the SLN metastasis (including two patients with
n-SLN macrometastases). It is possible that erroneous SLN
identification had occurred in the patients with macrometas-
tases. Nevertheless, excluding these two patients does not sig-
nificantly detract from our observation that n-SLN involve-
ment is not uncommon when sensitive techniques are used.
Large n-SLN metastases in micrometastatic SLN involvement
have been noted previously, including n-SLN metastasis in
cases with single cells in the SLN.7
“On the basis of our findings and the literature data, we
find it premature to conclude that axillary dissection may
be avoided in patients with T1–2 tumours and sentinel
lymph node micrometastases, as suggested by Chu et al
and Reynolds et al”
In our study, LNs with radioactive tracer uptake were desig-
nated as SLNs, the blue dye served only as a visual aid in iden-
tification. Other workers have in some instances included
blue, non-radioactive nodes as SLNs, a practice that has been
challenged.18 19 From a conceptual viewpoint it could be argued
that there can only be a single “true” SLN and that all other
nodes are non-sentinel nodes. If this line of reasoning is pur-
sued, two of seven patients from our group without n-SLN
involvement would have to be considered as having n-SLN
involvement. Conversely, it has been shown that more than
one first echelon node (SLN) may be present. In accordance
with these observations we chose to accept multiple SLNs.
We found that n-SLNmetastases as clusters were associated
with tumours > 2 cm in size and with high grade tumours.
Other groups have not found tumour grade to be an
independent risk factor for n-SLN metastasis.18 20 21 This is sur-
prising, because grade has been shown to be associated with
an increased risk for nodal metastases in small tumours.22 23
The term micrometastasis has only been defined arbitrarily,
and its definition varies between studies. A cut off point of
2 mm has been used in many studies and is included in the
TNM classification.16 24 25 Alternatives, such as the area of
lymph node involved by tumour and the particular pattern of
lymph node involvement, have been suggested.19 26–28 The
importance of micrometastatic disease and the implications
for treatment when it is demonstrated hinge upon delineating
the biological behaviour of small tumour deposits and small
numbers of isolated tumour cells.12 Experimental studies sug-
gest that most isolated (circulating) tumour cells are not
viable and will not result in metastatic disease. Thus, in the
strictest sense, a micrometastasis requires the arrest of
tumour cells in the tissue and proliferation.4 16 Biological char-
acteristics such as viability, angiogenic capacity, and avoidance
of the host immune reaction may be equally important
factors.29 30 In addition, it may be necessary to look at the host
lymph node response, because this may also influence the
ability of a micrometastasis to expand.26 In this setting, it is
interesting to note that Colpaert et al found a survival advan-
tage for patients with SLN micrometastases and hypothesised
that this may result from an enhanced host immune
response.31
Whatever the outcome of single tumour cells in the circula-
tion or in organs may be, it should be appreciated that the very
fact that they are detected implies that access to the lymphat-
ics or blood vessels has been gained, and that a line of defence
has been breached in the metastatic pathway.
The incidence of n-SLN involvement varies in reports and
this is in part a result of the sensitivity of the detectionmethod
used. Naturally, more intensive analysis of LNs with serial sec-
tioning and immunohistochemistry will reveal more meta-
static disease, as has been shown in SLN research.9 10 Reynolds
et al did not observe n-SLN metastases in 18 patients with T1
tumours and micrometastases in the SLN. They propose that
axillary lymph node dissection may not be necessary in
patients with T1 breast tumours and SLN micrometastases.21
Likewise, Chu et al found that less than 5% of patients with T1
tumours and only 6% of patients with T1–2 tumours and
micrometastatic SLN disease had n-SLN involvement, and
they also suggest that axillary lymph node dissection may not
be necessary in these patients.18 20 However, the methods used
in their study, with one or two sections for each n-SLN and
without IHC, probably underestimated the extent of n-SLN
disease.20 The same investigators in Giuliano’s group later
found that 24% of patients with T1–2 tumours and microme-
tastases in the SLN (either detected by H&E staining or IHC)
harboured n-SLN metastases. In that study, two level IHC was
used, which may have increased the sensitivity. However, they
did find that when lymphatic vascular invasion and extran-
odal hilar tissue invasion were taken into account only one of
58 patients with T1–2 tumours had an n-SLN metastasis.32
Another study, examining n-SLN involvement in patients with
positive SLNs, found n-SLN involvement in 27% of patients
with a single SLN harbouring a metastasis < 1 mm.28 In our
series, three of 21 patients with T1 tumours and an SLN
micrometastasis had n-SLN metastases detected by serial sec-
tioning and IHC. On the basis of our findings and the
literature data,28 we find it premature to conclude that axillary
dissection may be avoided in patients with T1–2 tumours and
SLN micrometastases, as suggested by Chu et al and Reynolds
et al.18 20 21 Indeed, if n-SLN metastases are relatively common
in patients with micrometastatic SLN disease and are likely to
be followed by axillary node dissection, then it is imperative
that the SLN is meticulously investigated. Therefore, the ques-
tion that must be answered is how thoroughly this must be
done and at what cost.33 The ultimate test of the importance of
Take home messages
• Non-sentinel lymph node (n-SLN) involvement is relatively
common in patients with breast cancer and sentinel lymph
node micrometastases
• Metastatic clusters in n-SLN are found more frequently in
patients with T2–3 tumours and grade 3 tumours
• Thus, axillary lymph node dissection is especially war-
ranted in these patients, but because n-SLN metastases
occur even in T1 and low grade tumours, these tumours
should be subjected to routine axillary dissection to achieve
local control
• Further studies are needed with larger series and patient
follow up to assess the clinical relevance of these findings
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SLN micrometastatic disease and its treatment implications
will be disease recurrence and disease related survival. For this
issue to be resolved, further studies are needed with larger
series and patient follow up. A trial incorporating these
aspects organised by the oncology group of the American Col-
lege of Surgeons is under way.34
. . . . . . . . . . . . . . . . . . . . .
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Abstract
Aim: To analyse causes of failure of sentinel node (SN) procedures in breast cancer patients and assess the role of pre-operative ultrasound
examination of the axilla.
Methods: In 138 consecutive clinically node negative breast cancer patients with the primary tumour in situ a SN procedure with radiolabeled
colloid and blue dye was performed. Radioactivity in the SN was scored as inadequate or adequate. The axillary lymph node dissection
scored for number of involved nodes and presence of extranodal growth.
Results: In 53/138 patients, the SN was positive for tumour. Full axillary node dissection revealed that 58/138 were node positive. So in five
patients the SN failed to predict true nodal status. In 3/5, the radioactive ratio (SN vs background) was inadequate. All were found to have
extensive nodal involvement. The radioactivity ratio was inadequate in 37/138 patients. This ratio was inadequate in 10 of 15 patients with
R4 positive nodes and 27 of 123 in patients with 0–3 positive nodes (p!0.001). If extranodal growth was present the radioactive ratio was
inadequate in 13 of 18 patients, whilst this was only the case in 24 of 120 patients without extranodal growth or metastases (p!0.001).
Ultrasound (US) examination and US-guided FNAC was able to pre-operatively identify 16 of the 26 patients with four or more metastases in
the axilla.
Conclusions: Extensive nodal involvement is an important cause of failure of the sentinel node biopsy. Pre-operative ultrasound examination
of the axilla can avoid this in almost two thirds of these patients.
q 2006 Published by Elsevier Ltd.
Keywords: Breast cancer; Sentinel node; Failure; Extra nodal growth; Extensive nodal involvement
Introduction
After the initial publication of the sentinel node (SN) in
penile carcinoma by Cabanas this hypothesis was tested for
other tumours.1 The SN is by definition the first draining
lymph node of the tumour site and histologic examination of
this node reflects regional lymph node status. This staging
procedure identifies the most significant prognostic factor in
breast cancer, melanoma and other solid tumours. In
melanoma and breast cancer, the SN biopsy has already
proven to be as accurate as a full lymph node dissection.2–6
At this moment SN procedure is standard of care in breast
cancer patients with acceptance of a false-negative rate of
5%. Failure of the procedure can be defined: (1) removal of
the wrong (non-sentinel) node or; (2) as failure to trace,
identify and remove the sentinel node. Failure can be caused
by anatomic factors7,8 and by technical inadequacies in any
of the three disciplines involved in the SN-procedure:
nuclear medicine, surgery and pathology. Most failures are
due to little or no experience with the various aspects and
intricacies of the procedure. Inadequacies in the nuclear
medicine part of the procedure are a result of the radioactive
dose, the amount of injected fluid and the injection
technique. Surgical causes are the technique used to trace
sentinel nodes during surgery, the time between injection
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and operation, whether lumpectomy was performed shortly
before SN biopsy and the presence of multifocal tumour.9–11
False-negatives may be due to inadequate histopathological
inadequate work-up method of the sentinel node to detect
(micro) metastases. In the literature, percentages of failure
range from 0 to 31% (Table 1). We evaluated the false-
negative procedures in our institutions and looked for
factors that might be responsible for removal of a non-
sentinel node. Ultrasound with fine needle aspiration
cytology (FNAC) of the axilla is part of the routine pre-
operative investigation. We have previously reported that
when US and FNAC demonstrate metastatic lymph node(s)
no SN procedure is performed and a full axillary lymph
node dissection is performed.12 However, initially we have
performed a SN procedure in ten of these patients. In one of
them the SN was negative while four other nodes contained
tumour. In another one the SN happened to be the only
tumour-free node.
We hypothesized that the following mechanism might be
operative: when the inflow of lymph into the SN is
completely blocked by tumour, it will be directed towards
another node. If a SN procedure is carried out in such
patients, both the radioactive tracer and the blue dye will
accumulate in the non-sentinel node, causing a false-
negative result. The aim of our study is to investigate the
role of this phenomenon in a consecutive series of patients




Between December 1996 and September 1998, 161
consecutive clinically node negative breast cancer patients
with the primary tumour in situ underwent ultrasound
examination and FNAC of the axilla. Cytological
examination showed tumour cells in 33 patients (no false-
positive results), in 23 of them no SN biopsy was performed,
so 138 patients were scheduled for SN biopsy.
Sentinel node identification
The sentinel node was identified with radiocolloid and
blue dye. On the day of the operation 3–4 ml 30–40 MBq
99m-Technetium nanocolloid was injected around the
tumour in healthy breast tissue. When the operation was
planned for the next morning, the amount of radioactivity
was doubled and injected in the afternoon. Two hours after
injection a lymphoscintigraphy was made to identify
location and number of the sentinel node(s). Visible nodes
were marked on the patient’s skin. After making the incision
in the axilla, the sentinel node was identified with guidance
of the RMD-CTC4 or C-trac probe and/or the blue stained
lymph vessels. The SN was identified and removed before a
routine complete axillary lymph node dissection (ALND)
was performed. The radioactivity ratio (SN vs background)
was measured by the probe in counts per second (cps).
Levels of activity
We distinguished two levels of activity: inadequate
(0–45 cps) and adequate ratio (O50 cps). This classification
is not based on any study but is raised by analysing the
counts per second. If a patient had adequate radioactivity
ratio, i.e. O50 cps, this was in all patients at least 80 cps.
Pathology
All axillary specimens were processed for histologic
examination using hematoxylin and eosin (H & E) staining
and examined by the pathologist. The sentinel node was
examined with multiple sections, 4–8 sections, and
immunohistochemical staining (IHC) using cytokeratine
antibody (CAM 5.2) in order to improve the detection of
(micro) metastases. On pathological examination the
number of involved nodes were counted and the presence
of extranodal growth (ENG) was recorded. Discrimination
between 1–3 andR4 positive nodes was made based on the
Dutch guidelines for adjuvant treatment.
Results
General
The mean age of the patients was 56 years (25–88). Mean
pathological size of the tumour was 20 mm (4–80 mm).
Half of the tumours were situated in the lateral upper
quadrant.
In 53 of the 138 patients, the SN was positive for tumour.
Examination of the preceding full axillary lymph node
dissection revealed another five node positive patients.
Table 1
Detection and false-negative rate of other groups investigating the value of
the SN procedure
N Traceable SN (%) False-negative rate (%)
Krag15 443 91 11
O’Hea16 60 92 15
Sato14 186 98.4 2.1
Tafra13 535 87 13
Cox11 466 94 1
Roumen17 83 69 3
Veronesi18 163 98 5
Flett19 68 82 17
Giuliano20 107 93 0
Albertini21 62 92 0
Borgstein9,a 112 93 2
Van der Ent22 70 100 4
de Kanter12 232 90 5
a Number of patients corrected, all 112 patients had a malignant tumour
and known results of the SN and ALND.
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Radioactive ratio
Adequate radioactive ratio was present in 101/138
patients. In 37/138 patients, the radioactive ratio in the
axilla was inadequate, 23 of these 37 patients were node
positive. No radioactivity was found in 11 patients, in five of
them there was a blue SN identified.
Both the presence of positive lymph nodes and presence
of extranodal growth were recorded. The influence of the
number of positive nodes and extranodal growth on level of
radioactivity in the axilla is shown in Tables 2 and 3.
Influence of the number of positive nodes
In Table 2, the influence of the number of positive nodes
on the amount of radioactivity is shown. In 10 of the 15
patients with four or more positive axillary lymph nodes
there was inadequate radioactivity. In the patient groups
with 1–3 or no metastases the ratio was inadequate in 27 of
123 patients, this is a significant difference (p!0.001). The
difference between 1–3 metastases and R4 is also
significant (p!0.025), the difference between 0 and 1–3
metastases is not significant.
Influence of the presence of extranodal growth
In Table 3, the influence of the presence of ENG on the
radioactivity in the axilla is shown. In 13 of the 18 patients
with ENG in one or more axillary lymph nodes there was
inadequate radioactivity. In the patient groups without ENG
or no metastases, the ratio was inadequate in 24 of 120
patients. Again, ENG vs no ENG and ENG vs no
metastases/no ENG is a significant difference.
US and FNAC
In Table 4, the results of the FNAC vs the number of
positive nodes is shown. This concerns the 161 patients
without a previous lumpectomy. Ultrasound examination
and FNAC can pre-operatively identify 16 of the 26 patients
with four or more metastases in the axilla.
False-negative sentinel nodes
As mentioned above, five patients had a false-negative
SN, i.e. the radioactive node was tumour-free while
metastases were found in one or more of the other axillary
lymph nodes. In 3/5, the radioactive ratio was inadequate,
all found to have extensive node involvement. In the two
patients with normal radioactivity, the failure was due to the
surgical procedure. In these patients lymphoscintigraphy
showed several nodes and at operation not all hot nodes
were removed and after the sentinel node biopsy the axilla
was not checked whether there was any activity left.
Discussion
Our postulated hypothesis seems to be correct. There is a
significant relationship between extend of nodal involve-
ment in terms of ENG and/or total number of positive nodes
and failure of the SN detection. The radioactivity is bound to
colloid and the colloid is phagocytosed by macrophages.
However, if the SN is completely replaced by tumour-cells
there is no healthy lymph tissue left to phagocytose the
colloid and radioactivity. The colloid will skip the SN and
be phagocytosed by another non-sentinel lymph node or will
not be phagocytosed at all. This will result in false-negative
sentinel nodes or non-detectable sentinel lymph nodes. An
example of this phenomenon is our observation in one of our
patients with a positive pre-operative ultrasound examin-
ation of the axilla and FNAC. The node identified by blue
staining whilst being not radioactive, was almost the only
tumour free node in the axilla. Another example is a patient
also with positive ultrasound and FNAC. In this patient, we
only injected the blue dye and again the found blue SN was
tumour free while four non-sentinel nodes contained
metastases. Alternatively, a SN replaced by tumour may
also lead to blockage of lymph flow and thus redirected
lymph flow away from SN towards another node. In a recent
case, not part of this series of consecutive patients, we found
blockage of lymph vessels by two small extranodally
intralymphatically located ‘in-transit’ tumour metastases
that lead to false-negative SN procedure.
To increase the accuracy of the SN procedure in the
patients with lymph node metastases injecting more
radiolabelled colloid will not solve the problem. Our
suggestion is to perform in clinically node negative patients
Table 2
Influence of the number of positive nodes on the radioactivity in the axilla
0 1–3C R4 Total
Inadequate (0–45 cps) 14 13 10 37
Adequate (O80 cps) 66 30 5 101
Total 80 43 15 138
Table 3
Influence of the presents of extranodal growth (ENG) on the radioactivity in
the axilla
ENG No ENG No metastases Total
Inadequate (0–45 cps) 13 10 14 37
Adequate (80 cps) 5 30 66 101
Total 18 40 80 138
Table 4
Result of the FNAC vs the number of metastases in the axilla
No metastases 1–3C R4 Total
Malignant 0 15 16 31
Not malignant 82 38 10 116
Total 82 53 26 161
A.Y. de Kanter et al. / EJSO xx (xxxx) 1–4 3
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an ultrasound examination of the axilla in combination with
fine needle aspiration cytology.
Tafra et al. reported their identification and false-
negative results in 529 patients were due to varies of
factors, the total number of positive lymph nodes!5 vsR5
did not reach statistical significance possibly due to the
small number of patients withR5 positive nodes.13 Sato et
al. studied the factors associated with the uptake of
radiocolloid by the sentinel node. Only age R65 years
and large SN of R8 mm was significant. Node positive vs
node negative did not reach statistical significance,
however, there was no discrimination between the number
of positive nodes.14 According to Sener et al. the reasons for
mapping failure are multifactorial, and it appeared that
mechanical obstruction of parenchymal breast lymphatics
was associated with mapping failure in 40% of patients with
more than 10 positive nodes.7
We reported previously on the results of ultrasound
examination of the axilla in patients with breast cancer.12
Non-metastatic lymph nodes are hard to detect; they have an
echo-rich, fatty centre, which is difficult to distinguish from
surrounding axillary fat tissue. Lymph nodes containing
tumour have an inhomogeneous structural aspect on
ultrasound. The more tumour is present the more
inhomogeneous the aspect. An inhomogeneous aspect is
even easier to detect with ultrasound if extranodal growth is
present. In most patients with extensive node involvement
there was extranodal growth. This combination reveals a
high ultrasound detection rate for patients with extensive
node involvement. In this study, ultrasound and FNAC was
able to pre-operatively identify 16 of 26 patients with four
or more metastases in the axilla.
In conclusion, failure of the sentinel node procedure;
non-detectable and false-negative sentinel nodes should be
as low as possible. Advanced nodal involvement (R4 nodes
or ENG) causes failure of the sentinel node biopsy in a
majority of patients. Changes in the procedure will decrease
only one parameter of failure. Both failure parameters will
decrease if the sentinel node procedure will be combined
with a pre-operative ultrasound examination of the axilla.
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CHAPTER 7
Is internal mammary chain sentinel node biopsy worth while? 
Outcome in 90 consecutive non-biopsied patients with a positive IMC scintigraphy. 
M.W.J.M. Wouters, M.B.E. Menke-Pluijmers, A.Y. de Kanter, H.G. de Bruin, L. Verhoog,  
A.M.M. Eggermont, A.N.van Geel. 
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Background: Although the status of the regional lymph nodes is the most important 
determinant of prognosis in breast cancer, harvesting sentinel nodes (SNs) detected in the 
internal mammary chain (IMC) is still controversial.  
Aims: The aim of this study was to determine in how many patients the identification of a 
positive IMC SN might change the systemic or locoregional therapy, with a possible benefit 
in outcome. 
Patients and methods: In a 6½ years period, data of all patients with T1-2 breast cancer, who 
had a SN procedure, were prospectively collected. In this period our policy was not to explore 
the parasternal region even if the IMC was the only localisation of a SN. 
Results: Of 571 patients scintigraphy indicated in 86 a hot spot in the IMC. In 64 of these 
patients the axillary SN was negative. Of these only 25 did not have an indication for adjuvant 
systemic treatment based on their tumour characteristics. From the literature is known that in 
axillary negative patients IMC metastasis are found in 0-10% of the cases. Therefore, routine 
IMC SN biopsies would only in 2 to 3 of our patients have resulted in the identification of an 
indication for adjuvant systemic therapy. During a median follow-up of 36 months no 
parasternal recurrences were found.
Conclusions: Routine performance of an IMC SN procedure is not necessary, because 
parasternal recurrences are very rare and only very few patients benefit in the sense that an 
indication for adjuvant systemic therapy is identified. 
Keywords: breast cancer, sentinel node biopsy, internal mammary lymph nodes, staging
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Introduction 
In breast cancer sentinel node (SN) biopsy of the axilla is a widely accepted procedure for 
staging purposes 1 2. The axillary lymph node status is one of the most important prognostic 
factors on which decisions about adjuvant treatments are based. However, dissemination of 
tumour cells through the lymph system is not only taking place to the axillary lymph nodes 
but also to the supraclavicular and internal mammary lymph nodes 3. Although studies of 
lymphatic drainage patterns report internal mammary chain (IMC) involvement in 13 to 35%, 
the value of a SN procedure for IMC is still controversial 4-8.
A survival benefit has not been observed after complete dissection of the IMC region 9-14.
Although adjuvant locoregional radiation therapy has proven to be beneficial after 
mastectomy 15-17, the contribution of radiation to the IMC to improve survival and recurrence 
rates, is still unclear. A tumour-positive IMC node could be a reason for selective IMC 
radiation. Several articles addressed this subject. Although IMC radiation might decrease 
loco-regional recurrence, there is no evidence for a beneficial effect on survival, while the risk 
of complications like pneumonitis and cardiac toxicity increase 18-22.
 Despite the lack of impact of surgical and radiation therapy for tumour-positive IMC 
nodes, the identification of these node-metastasis might be important for an other reason 11 23.
The tumour status of IMC nodes does have a prognostic value, which is comparable to that of 
the status of the axillary lymph nodes 10 24 25 . Especially for axillary node negative patients, 
with SNs in the IMC on lymfoscintigraphy, stage migration could be the result of harvesting 
these nodes 26 27. Upstaging is seen in 7–17 percent of the patients in who an IMC SN is found 
8, 27.
 So, an IMC SN procedure might promote accurate staging. However, we must take account 
of the shortcomings of the procedure. Although it is possible to identify and selectively 
remove IMC SNs with minimal morbidity, complications are reported in 2.2% to 8% of the 
cases 8 27 28 46. Only a therapeutical benefit justifies such extra morbidity. 
 Because of the failure of studies to demonstrate any significant survival benefit, in the past 
our policy was not to remove IMC SNs visualized on the lymphoscintigraphy, even when 
axillary nodes were negative. 
The purpose of this study was to determine in how many patients the identification of a 
positive IMC SN would have changed the systemic or locoregional therapy, which might have 
resulted in a benefit in outcome. 
Patients and Methods 
Since July 1997 an axillary SN biopsy is the standard staging procedure for patients with 
T1 or T2 breast cancer in our hospital. Prior to surgery ultrasound of the axilla is routinely 
performed with additional fine needle aspiration if suspicious lymph nodes are seen 29. When 
this reveals an axillary lymph node metastasis, the SN procedure is abandoned and an axillary 
lymph node dissection (ALND) is performed. All patients without FNA proven lymph node 
metastasis get a SN procedure. On the day of the operation 39 MBq Technetium-99M is 
administered in 3 peritumoral injections. In case of nonpalpable breast cancer the peritumoral 
injection is guided by ultrasound or stereotaxis. After 2 hours a lymphoscintigraphy is made 
to identify the routing of the colloid and the subsequent SN (Figure I). The anterior and lateral 
images are preoperatively shown and described to the surgeon by the nuclear specialist. Also, 
the locations of SNs are marked on the skin with indelible ink and during surgery confirmed 
with a hand-held gamma-probe. Just before surgery, 1.0 mL of Patent Blue is injected 
intradermal above the tumour. The SN biopsy of the axilla is performed before surgery of the 
breast, with a frozen section of the SN, that if found tumour-positive, leads to an ALND. Post-
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operative, the frozen-section is followed by further pathologic evaluation, cutting the node at 
a minimum of six levels and hematoxylin-eosin and immunohistochemical staining. 
Secondary found SN metastasis also lead to ALND. 
 All patients with a SN procedure in the period July 1997 to November 2003 were included 
in a prospective database. In this period our policy was not to explore the parasternal region 
even when the IMC was the only localisation with a hot spot on lymphoscintigraphy. To 
evaluate this policy we selected all patients with an IMC SN on the lymphoscintigraphy from 
our prospective database. For these patients the following data were collected; date of birth, 
date of the SN surgery, pathological N status, pathological characteristics of the primary 
tumour (tumour size in mm, differentiation according to Bloom and Richardson I, II and III, 
Mitotic Activity Index, Estrogen and Progesterone receptor status), radiotherapy and adjuvant 
systemic therapy (yes or no), clinical signs of IMC node recurrence and if performed date and 
results of CT scans of the chest and bone scans. If any of these data could not be found in the 
pathology or radiology reports, the histological material was reviewed by a pathologist and 
the images were reviewed by a radiologist. 
Figure I 
Lymphoscintigraphy in a breast cancer patient showing the axillary and the internal mammary 
chain lymph nodes  
The pathology reports of all patients with an IMC SN on the lymphoscintigraphy were 
reviewed and the indication for adjuvant systemic therapy was reconsidered based on the 
most recent guidelines in the Netherlands 30. These guidelines (Figure II) are a result of a 
multidisciplinary consensus derived from the evidence-based literature. 
Results
From 1 July 1997 to 1 November 2003, a SN procedure was performed in 571 consecutive 
patients. In 481 of these patients there was only an axillary lymph node visualized on the 
nucleotide scan. In 89 patients both an axillary and an IMC SN were detected. In 1 patient 
AXILLA
TUMOURIMC
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only an IMC SN was seen and this patient was also included in the study. All but one of these 
90 patients were female. The age at the time of SN biopsy was 31-85 (mean 50) years.  
In 4 of 90 patients the definitive pathological diagnosis showed no invasive breast cancer (2 
patients with severe sclerosis, 1 patient requested a prophylactic mastectomy and SN biopsy, 
and 1 other patient had DCIS with a positive SN). These patients were excluded, leaving 86 
patients in the study. 
Figure II
Current Dutch Guidelines for the treatment of breast cancer 34
Adjuvant systemic treatment in node negative breast cancer and age >35 years 
Tumour 
size
Differentiation (SBR) and age 
 BR I  BR II BR III 
� 1 cm - - - 
1-2 cm -        (� 35y see N+) -        (� 35y see N+) See N+ 
2-3 cm -        (� 35y see N+) See N+ See N+ 
> 3 cm See N+ See N+ See N+ 
Adjuvant systemic treatment in node positive breast cancer (all ages) and N0 (� 35years)
Receptor status Menopausal status 
 Premenopausal Postmenopausal 
  50-59 years 60-69 years �70 years 
ER+ and/or PgR+ N � 1: CT and 
HT
N � 1: CT and 
HT
N 1-3: HT
N � 4: CT and      
HT
N � 1: HT 
ER- and 
PgR-
N � 1: CT N � 1: CT CT N � 1: no advice 
possible 
Legend; BR=differentiation according to Bloom and Richardson (I, II and II); N=Nodal stage; 
ER=Estrogen Receptor; PgR=Progesterone Receptor; CT=Chemotherapy; HT=Hormone 
Therapy
In 64 of 86 patients (74%) the axillary SN was negative. The other 22 patients (26%) had a 
tumour positive axillary SN and consequently they underwent an ALND and received 
adjuvant systemic treatment. Another 27 patients received adjuvant systemic treatment on the 
basis of the characteristics of the primary tumour, in line with the national guidelines at that 
time. Therefore, 37 patients (43%) did not have an indication for adjuvant systemic therapy. 
Under the current guidelines, last revised in 2004 (Figure II), this number would be reduced 
to 25 (29%). These are of special interest because information about the IMC status could 
change the management of these patients. Upstaging from N0 to N+ status could mean an 
indication for adjuvant systemic treatment (Figure III). 
In the absence of information about the IMC status, none of the patients received selective 
parasternal radiotherapy. Neither was the IMC irradiated as part of regional radiotherapy. For 
various reasons 3 patients received postoperative chest wall irradiation, and 24 patients 
underwent radiotherapy as part of breast-conserving therapy. 
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The median follow-up time was 36 months (range 3-89 months). According to the national 
guidelines patients had a physical examination every 3 months and radiological imaging of 
the breasts every year. Further imaging was only performed on indication, such as pain, 
swelling and various other reasons. A CT-scan of the chest was performed at any time during 
follow-up in 35 cases. No IMC recurrences were found. We did find one patient with clinical 
signs of a possible parasternal recurrence, but in this case a sternal metastasis with 
pathological fracture was diagnosed, as a part of wide-spreaded bone metastasis. There were 
no signs of IMC metastasis on this patient’s CT scan. The other CT scans, which were revised 
especially for this study, did not show enlarged IMC nodes, both in their primary and 
secondary  assessment. 
Figure III 
Break down of the number of Internal Mammary Chain Sentinel Nodes of 86 patients 
according to the indication for adjuvant systemic therapy. 
Abbreviations; AX=axillary, IMC=internal mammary chain, SN=sentinel node, *present 
indication according to the national guidelines published in 2004. 
Discussion
In our series of 571 patients the lymphoscintigraphy showed an IMC SN in 90 cases (16%). 
We did not see a single case with clinical signs of IMC metastasis at a mean follow up of 41 
months. Not a single parasternal metastasis was diagnosed in spite of the fact that none of our 
patients received radiotherapy to the IMC, after surgery. Though, the status of the IMC SNs 
could be relevant in another way. Exploration of the IMC could improve staging, which is 
especially important when upstaging leads to a change in management of the patient. 
From the literature is known that treatment of the IMC, either by surgery or by 
radiotherapy, does not improve survival. Veronesi et al. reported 56 patients with positive 
IMC SN 
N = 86 
Axilla SN negative 
N = 64 
Axilla SN positive 
N = 22 
Adjuvant therapy 
yes   N = 22 
Adjuvant therapy 
yes   N = 39 
Adjuvant therapy  
no   N = 25 
IMC SN negative 
N = 22 
IMC SN postive 
N = 3 
New indications  
adjuvant treatment 
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axillary nodes who had undergone either quadrantectomy with axillary node dissection or 
Halsted’s mastectomy. Patients were randomized to receive either postoperative radiation 
therapy to the supraclavicular and IMC nodes or no further treatment. Survival curves at ten 
years showed no advantage with adjuvant radiation therapy to these sites 31. Palmer and 
Ribeiro reported a much larger prospective randomized trial for postoperative radiation to the 
axilla, supraclavicular and parasternal region, which also failed to show a difference in 
survival even after 30 years follow-up 32. Host et al. confirmed the absence of a survival 
benefit in the long-term results of the Oslo study, but found a lower incidence of loco-regional 
recurrence 22.
Also, in more recent literature, authors state that an IMC SN procedure leads to a better 
selection of patients who might benefit from postoperative radiotherapy to the parasternal 
region 8 27 46.
In our series, we looked into the 90 cases of hot spots in the IMC. Since patients did not 
receive parasternal radiotherapy, possible microscopic disease in the IMC nodes was left 
untreated. Although the IMC could have received some irradiation dose in breast conserving 
treated patients, we did expect some cases of parasternal recurrence during follow-up. Based 
on the literature we can assume that 9 to 30 percent of our patients had metastasis in the IMC 
nodes shown on the lymphoscintigraphy 8 10 24 36 44. But, calculating with these percentages we 
must take into account that the technique for detecting and harvesting IMC SNs differs 
greatly. In our series of 571 patients the lymphoscintigraphy was suggestive for an IMC SN in 
16% of the cases. This was the result of the use of 39 MBq injected peritumorally. Others 
report a detection rate of 25% using a ten times higher dose of technetium-99m 6. The 
subsequent biopsies have different success rates, ranging from 63 to 97 percent 6 8 27 45.
Variations in technique give different procedure outcomes. But, because most series report a 
visualization rate between 5 and 20%, we may conclude that above mentioned percentages are 
applicable to our series 9. Untreated, one expects this metastasis to grow and lead to 
locoregional symptoms. In subsequent imaging it could be difficult to differentiate a sternal 
erosion or solitary bone metastasis from a lymph node recurrence. But, in our series we had 
only 3 patients with a sternal lesion, and all had widespread bone or visceral metastases. 
According to the definition used in the literature, these patients are not considered to have a 
lymph node recurrence in the IMC 33,34. Other reports confirm that only a fraction of 
(micro)metastasis in the IMC become clinically evident 35.
Just like the nodes in the axilla, IMC nodes do have a prognostic value. Veronesi et al. 
found in their analysis of 1119 patients that survival was significantly affected by the 
presence of positive IMC nodes. 10-year survival varied from 80% in patients with axillary 
and IMC negative nodes, 55% in axillary positive and IMC negative nodes, 53% in IMC 
positive and axillary negative patients and 30% in patients with both axillary and IMC 
positive nodes 36.
Therefore, the failure of recognizing an IMC positive node, could lead to under-staging. In 
Veronesi’s series 9% of the patients had negative axillary and positive IMC nodes. Other 
articles report slightly lower percentages of 2 to 8 % 8 10 28 37. In this group under-staging 
could lead to under-treatment, because a node positive status is one of the main indications for 
adjuvant systemic treatment. 
In our series of 86 patients with breast cancer and an IMC SN on the lymphoscintigraphy, 
there were 64 patients (74%) with a tumour negative SN in the axilla. Without information 
about the IMC status, 39 of these patients would have had an indication for adjuvant systemic 
treatment, based on most recent Dutch guidelines (Figure I) 30. So, 25 patients would not 
receive adjuvant treatment. In the literature cases with no axillary metastases in which IMC 
metastasis changed the N0 to a N+ status, were found in 0% to 10% of these patients (Figure 
IV). So, if in one tenth of the 25 patients the N status turns positive, 2 to 3 of the original 64 
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axillary negative patients could benefit from the IMC SN procedure (5%). They are the ones 
who ‘gain’ an indication for adjuvant systemic treatment. The other 61 biopsies will be 
without any therapeutic consequence. 
The possibility to define a subgroup of patients which can be selected to perform an IMC 
SN procedure on the basis of localisation, size, grade or other characteristics of the tumour is 
still questionable 5 10 38-40.
Figure IV
Results of lymph node biopsies of the Internal Mammary Chain in the literature 
Article SN 
procedures








Goyal, 2005 5� ��39 �20 58 8 5
Farrús, 2004 52 225 20 �4 2 0
Lawson, 2004 53 �75 �0 6 0 0
Estourgie, 2003 8 69� �50 �30 22 9
Galimberti, 2002 29 n.r. �82 �60 �4 4
Ent v.d., 200� 6 256 65 4� �� 3
Dupont, 200� 54 �273 n.r. 30 5 3
Dupont, 200� 22 �470 n.r. 36 5 2
Johnson, 2000 55 80 �0 �0 3 0
Noguchi, 2000 56 4� 5 5 0 0
Winchester, �999 58 �80 20 20 3 0
(0-30%) (0-�0%)
Abbreviations: IMN = Internal Mammary Node, SN = Sentinel Node,
lymphosc. = lymphoscintigraphy, n.r. = not reported 
Non palpable medial tumours might drain more often to the IMC nodes independent of 
tumour size 6,41. There are three reports on the influence of tumour location on IMC 
metastases in axillary node-negative patients 42-44. Two of them show no difference in the 
incidence of IMC metastases between medial and lateral primary tumours. The other one, 
from Li in 1984, showed from 1242 cases of extended radical mastectomy for medial tumours 
8 percent IMC positive nodes versus 2 percent for lateral tumours. 
In addition, if size, grade and receptor status are known prior to the SN procedure, harvesting 
an IMC SN can be abandoned when an indication for adjuvant systemic treatment is already 
present. Accurate imaging and a histological biopsy is needed to obtain this information 
preoperatively. If such a biopsy would be successful in 100% of the cases, the number of SN 
biopsies, relevant for the management of the patient, could be reduced significantly. If we 
could have selected the 25 patients in our series, for whom the tumour characteristics where 
no indication for adjuvant systemic therapy, we could have restricted the IMC SN biopsies to 
these patients. With a tumour positive IMC SN in 2 to 3 patients, we would still have 
performed 10 biopsies to find 1 tumour positive SN. 
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That these results are not theoretical is confirmed by earlier studies 23,45. In the UK 
ALMANAC multicenter trial, in which 1139 patients had a SN biopsy for T1-T3 breast 
cancer, there was IMC node drainage in 120 (10.5%) of the patients, of which 60 where 
biopsied. Only 4 (7%) of these patients had a change in management, meaning a ‘new’ 
indication for systemic therapy. 
Conclusion
Based on our series and a review of the literature we conclude that the indication for an 
IMC SN procedure is very limited. For only 2 to 3 of our 571 patients (0,5%) harvesting an 
IMC SN could have been beneficial. If tumour characteristics are known prior to the 
procedure, a further selection of patients might be possible. But even then, of the patients in 
whom an IMC SN is successfully biopsied only 7 to 10% might benefit as a result of adjuvant 
therapy. On top of the futile therapeutic contribution one should be aware of introducing a 
procedure which, like any other procedure has complications. 
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Abstract
Aim: To report the long-term results of sentinel node negative breast cancer patients treated without axillary lymph node dissection and the 5-
year follow-up results of 149 patients.
Methods: The incidence of axillary—and local recurrences and second ipsilateral primary tumours was evaluated. The added value of annual
ultrasound of the treated axilla, being part of the standard follow-up, was also evaluated.
Results: After a mean follow-up of 65 months (50–79) axillary recurrences were observed in four patients, local recurrences or ipsilateral
second primary tumours were diagnosed in another seven patients. All axillary recurrences were diagnosed because of a palpable axillary
mass; ultrasound in combination with fine needle aspiration cytology did not have an added value.
Conclusion: It can be concluded that the incidence of axillary recurrences after negative SN is much lower than expected. There is no added
value of US and FNAC of the axilla in the routine follow-up of SN negative patients.
q 2005 Elsevier Ltd. All rights reserved.
Keywords: Sentinel node; Breast cancer; Follow-up; Ultrasound; Recurrence
Introduction
Since, the introduction of the SN in breast cancer patients
byGiuliano andKrag in the early 1990s,1,2 the SN has proven
to be a valuable tool in predicting the status of the axilla.3–5
After a validation period many institutes abandoned
standard ALND as a staging procedure. Only in those
patients with a positive SN ALND is performed. The SN
biopsy became routine practice despite lack of long-term
follow-up results concerning local control and overall
survival. The meaning of isolated tumour cells and even
micrometastases in the SN is still uncertain and topical
subject in many discussions. Future studies should define
the management of these metastases. Up until now there is
no standard treatment of axillary- and local recurrences. For
instance, in case of a local recurrence in the breast the
necessity of ALND is still discussed.
Our study reviews all clinical data and follow-up
collected in 149 patients with SN negative invasive breast
cancer.
Because of our positive experience with ultrasound
(US) examination of the axilla combined with
fine needle aspiration cytology (FNAC) in the pre-
operative detection of axillary lymph-node metastases,6
we incorporated this procedure in our follow-up
routine.
The purpose of our study was to evaluate the value of US
combined with FNAC in the follow-up and our axillary
recurrence rate.
Patients and methods
Between November 1998 and May 2001 160 clinically
node negative, operable breast cancer patients underwent
SN biopsy that revealed a negative histological status. No
further ALND was performed. Part of the work up was
US examination of the axilla and in case of visible nodes
FNAC was performed. In case of pre-operative positive
US-FNAC patients were scheduled for ALND. In all
other cases SN biopsy was part of the operation. Eleven
patients were followed-up in other hospitals; leaving 149
patients for evaluation.
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Our SN biopsy technique is described in detail before.5 In
short the procedure included peritumorally injection of
39 MBq 99m-Technetium nanocolloid (Solconanacoll) at
least 2.5 h before the operation. Two hours post-injection a
static lymphoscintygraphy was made. Prior to the operation
1 ml Patent Blue was injected intradermally above the
tumour. Subsequently, the SN was identified with guidance
of a Europrobe and the blue-stained lymphvessels. In case of
internal mammary chain hotspots, no attempt was made to
trace and remove these lymph nodes. The SN biopsy of the
axilla is performed before surgery of the breast, with a
frozen section of the sentinel node, that if found tumour-
positive, leads to a level I and II axillary lymph node
dissection. In case of negative frozen-sections, further
pathologic evaluation, cutting the node at a minimum of six
levels and hematoxylin-, eosin and immunohistochemical
staining is followed. Patients with secondary found (micro-)
metastasis were offered ALND in a separate operation
session.
Adjuvant treatment and follow-up
The decision for adjuvant systemic therapy was
individualized and made by the medical oncologist and
the patient. External beam radiation was part of breast
conserving therapy. Patients received 50 Gy to the whole
breast with tangential fields, with a boost to the tumour bed
to a total of 65 Gy.
The follow-up consisted of taking history and physical
examination every 3 months during the first 2 years and
subsequently every 6 months, combined with an annual US
examination of the axilla and mammography. In case of US
visible lymph nodes FNAC was performed.
Results
Mean age of the 149 patients was 55 years (29–82). The
median tumour size was 1.2 cm, 56% were T1c tumours.
Eighty-four patients (56%) choose breast-conserving
therapy. Histopathological examination showed ductal
carcinoma in 122 patients, the Bloom–Richardson was
mostly grade II. Only 20 patients (13%) received adjuvant
systemic treatment mostly because of tumour character-
istics. The mean follow-up was 65 months (50–79).
Axillary recurrences
During follow-up axillary recurrences were observed in
four patients. In three patients, the initial treatment was
ablation. All initial tumours were small (10, 15, 16 and
17 mm), Bloom–Richardson grade I or II and the ER was
positive in all four cases. All patients were analysed because
of a palpable lymph node in the axilla. Time to axillary
recurrence was 10, 12, 14 and 56 months. After positive
cytology, all patients underwent ALND. In all patients there
were at least two positive lymph nodes. Decisions for
adjuvant treatment depended on the pathological results,
three patients received chemo-, hormonal- and radiotherapy
and the fourth patient received only hormonal therapy.
Unfortunately, one patient developed brain- and bone
metastases 27 months after her axillary recurrence. Up
until now the other three patients are free of disease 6, 45
and 49 months after their delayed axillary treatment.
Local recurrences
Local recurrences or ipsilateral second primary tumours
were diagnosed in seven patients. Ablation was in three
patients the initial treatment. The initial tumour ranged
from 10 to 25 mm with all but one positive ER. The
recurrences were detected due to a palpable mass
(five patients), ultrasonographically metastatic axillary
lymph nodes (NZ1) or screening mammography (NZ1).
Time to local recurrence was 18, 26, 33, 38, 39, 53 and 59
months. Treatment consisted of ablation of the breast
including ALND in case of primary breast conserving
therapy. In case of primary ablation local resection and
ALNDwas performed followed by radiotherapy of the chest
wall. In one patient no ALND was performed in dialogue
with the patient because of indistinction about the necessity.
Pathological examination of the ALND showed in four
patients metastases. Decisions for adjuvant treatment
(chemo-, hormone and/or radiation of the axilla and
supraclavicular region) depended on the pathological
results. One patient, primary treated with ablation and SN,
developed sternal pain a few months after resection of her
medial located recurrence. Cytology revealed sternal
metastatic cells and because screening for distant metastases
was negative she was treated with 50 Gy to the sternal bone.
No adjuvant hormonal treatment was given because of
negative receptors, patient refused adjuvant chemotherapy.
One year after ending radiation treatment she developed
supraclavicular metastases and started treatment with
Herceptin.
Screening for distant metastases after the surgical
treatment of the recurrence, was positive (lung and liver
metastases) for another patient and she was treated with
systemic therapy. Up until now the other five patients are
free of disease 16, 17, 25, 38 and 60 months after their
recurrence treatment.
Annual ultrasound examination of the axilla
In order to detect axillary recurrences as soon as possible,
annual US examination of the treated axilla was part of the
follow-up. Unfortunately, this examination was not per-
formed in 48 patients due to several reasons. The US
combined with FNAC was only once positive in only one of
101 patients. This patient had axillary lymph-node
metastases of a pathologically proven second primary
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breast tumour. In three of the four axillary recurrences
patients detection of the palpable lymph nodes was before
the scheduled annually ultrasound. The fourth axillary
recurrence patient had three US examinations and once
there was a visible node with benign characteristics and
negative FNAC, a few months after her last US examination
there was a palpable axillary lymph node. Subsequent
ALND revealed two metastatic lymph nodes. In all other
100 patients the more than 200 US examinations and 43
FNAC yielded no positive cytology.
Discussion
The sentinel node concept, firstly described by Cabanas
in 1977,7 is extensively studied in breast cancer. Because of
the results the SN procedure replaced ALND as standard
axillary staging procedure with acceptance of 5% axillary
recurrences. Since, this replacement attention was focussed
on the incidence of axillary recurrences in SN negative
patients treated without further ALND. As we know from
the literature, the incidence of node positive patients is
about 40%. However, the incidence of axillary recurrences
in breast cancer patients without treatment of the axilla is
7–18% after a median of 14.7–31 months at a follow-up of
63–126 months.8,9 Apparently, not all tumour cells found
with pathological examination are potentially metastatic.
Although ALND is performed to reduce the number of
axillary recurrences, the incidence is still 0–2.1% at follow-
up of 40–180 months. The influence of surgical- and
adjuvant treatment on overall survival is unclear because of
the small numbers of patients and change of single- towards
multimodality treatment approach.8,10–16
At best the incidence of axillary recurrences after
negative SN biopsy is as low as after ALND. Up until
now, the reported studies concerning follow-up after
negative SN show comparable good results (Table 1).
Although our incidence is 2.7%, compared with the other
reported results it is at least doubled but clearly lower than
the expected 5%. This is partially explicable by our long
follow-up and less adjuvant systemic treatment. Since
January 2005, the indications for adjuvant systemic
treatment are extended.
On the basis of the reported data it can be concluded that
the incidence of axillary recurrences after negative SN is
much lower than expected. Possible explanations are: a
lower incidence of false-negative SN procedures than the
5% during the validation period, partially irradiated axilla in
patients treated with breast conserving therapy due to
tangential radiation fields, extending the possibilities of
chemo- and/hormonal adjuvant therapy and the lower than
expected capacity of tumour cells to develop into
metastases.
Besides the sensitivity and the incidence of axillary
recurrences the outcome of those patients who have
developed an axillary recurrence was of great concern
during and after the validation period. To date the follow-up
of SN negative patients is too short to give an answer.
However, the reported incidence is as low as after ALND
Table 1
Reported axillary recurrences






% Time to axillary
recurrence
(months)
LR DM Mean FU
(months)
Badgwell20 159 0 0 – 1 4 32 (24–43)
Blanchard21 685 1 (abl) 0.14 41 5 8 28 (7–46)
Chung22 208 3 (bct, 2!n.m.) 1.44 4, 11, 40 0 3 26
Jeruss23 592 1 (abl, CT, HT) 0.17 22 n.m. n.m. 27.4 (1–98)
Kokke24 113 1 (abl, CT) 0.88 29 1 0 37 (24–53)
Langer25 122 1 (bct, CT, HT) 0.82 14 6 3 42 (12–64)
Naik26 2340 3 (3!bct, 1!
HT)
0.13 18, 29, 38 n.m. n.m. 31 (1–75)
Reitsamer27 200 0 0 – 0 n.m. 36 (22–56)
Roumen28 100 1 (abl) 1 14 1 1 24 (16–40)
Sanjuan29 159 1 (bct, CT) 0.63 19 n.m. n.m. 21 (4–45)
Schrenk30 83 0 0 – 0 0 22 (4–48)
Smidt31 439 2 (2!abl, 1!
HT)
0.46 4, 27 n.m. n.m. 26 (1–90)
Torrenga32 104 1 (bct, syst) 0.96 24 n.m. 3 57 (48–83)
van der Vegt33 107 1 (bct) 0.93 26 n.m. n.m. 35 (17–59)
Veronesi34 953 3 (abl, 2!bct,
1!HT, 1!CT)
0.3 26, 29, 37 12 22 38
Zavagno18 479 0 0 – n.m. n.m. 36 (12–68)
De Kanter 149 4 (3!abl, 1!
bct)
2.68 10,12,14, 56 7 9 65 (50–79)
Abbreviations: LR, local recurrence; DM, distant metastases; FU, follow-up; abl, ablation; bct, breast conserving therapy; CT, chemotherapy; HT, hormonal
therapy; syst, systemic therapy; n.m., not mentioned.
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and the influence on overall survival of axillary recurrences
after ALND is still unknown.
Because of our pre-treatment US results (sensitivity
57%)17 and our false-negative percentage during the
validation period (5%),5 part of the follow-up of SN
negative patients was US examination of the axilla
combined with FNAC in case of visible lymph nodes, as
mentioned above. With this procedure we hoped to detect
axillary recurrences before they were clinically present in
order to prevent simultaneous distant metastases and
worse prognosis. However, none of the patients with
axillary recurrences were detected with US. Moreover,
the patients with visible nodes were anxious about the
results that were in all cases benign. These disappointing
results combined with the reported low incidence of
axillary recurrences and the fact that treatment is still of
curative intent, we decided that US and FNAC was no
longer part of the standard follow-up. Only two other
studies after the incidence of axillary recurrences used
US of the axilla is in the follow-up. However, both
studies had no axillary recurrences.18,19
An other unsolved issue is the management of the axilla
in SN negative breast cancer patients with a local recurrence
in the breast or on the abdominal wall.
Should re-SN or ALND be considered? In our study, in
four out of six patients lymph-node metastases were found
after ALND. This might suggest a possible role for re-SN
staging, but in the one patient where we tried no SN could be
identified.
In conclusion, the incidence of axillary recurrences after
negative SN without proceeding ALND is lower than
expected, in case of an axillary recurrence this can usually
be treated by routine ALND. Whether one can determine its
potential impact on survival is uncertain in view of the
scarcity of these axillary recurrences. There is no added
value of US and FNAC of the axilla in the routine follow-up
of SN negative patients.
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 In the recent years the surgical treatment of breast cancer has changed towards a less 
invasive and less mutilating procedure. Breast conserving therapy and the introduction of the 
sentinel node (SN) procedure are the two most important changes. The introduction of a new 
technique is a time consuming procedure. First it should be developed and evaluated in a local 
situation. If the new technique is believed to be better than the standard treatment, the 
technique should be come available if possible after a randomised controlled trial for all 
patients concerned.  In CHAPTER 2 the introduction of the SN procedure in three 
participating hospitals (a large teaching hospital, a cancer centre and a university hospital) is 
described. Special attention was made on the role of a co-ordinator to assure standardisation 
and quality control in this multicenter study. The role of the co-ordinator was two folded; 
firstly the supervision of the implementation in the several involved departments and secondly 
to refine the procedure upon the collected data. During our study we adjusted several aspects 
of the procedure: the concentration of the colloid in the radioactive solution, the injection of 
the blue dye intracutaneously after disappointing results of the peritumoral injection and, in 
cases of a preceding lumpectomy, a cranial injection to the scar because of failure of the 
caudal injections. With these corrections the results became excellent.  
In the end the results of the procedure (sensitivity and false negativity) were the same for the 
three participating hospitals. 
 Based on this experience an implementation project was started with the support of the 
Comprehensive Cancer Centre Rotterdam. The regional hospitals implementing the SN 
procedure were recommended to perform during the learning curve a double procedure (SN + 
axillary lymph node dissection (ALND)) of 50 patients. The hospital could proceed with SN 
biopsy only if less than 5% false-negative results were obtained, all patients were registered 
centrally and were able to be followed adequately. 
Special recommendation was made towards ultrasound of the axilla during follow-up with the 
expectation to detect a regional recurrence in an earlier phase. 
 The SN procedure is complex and time consuming. It has several disadvantages such as 
low identification rate in extensive axillary lymph node metastases, false negative results, 
need for radioisotopes and requirement of frozen-section histological analysis. For this reason 
it would be valuable if SN biopsy could be replaced by easier methods. In a study before the 
era of SN biopsy preoperative ultrasound of the axilla in combination with fine needle 
aspiration cytology (FNAC) had proven to be a method with a low sensitivity but with a 
specificity of 100 per cent. Therefore this examination was part of the SN procedure in the 
multicenter study after the value of the SN biopsy in clinically node negative operable breast 
cancer patients. When metastases in the axilla were demonstrated, the SN biopsy was not 
relevant any more for the clinical decision making.  
 In CHAPTER 3 the results of the ultrasound and FNAC were evaluated. The echo pattern 
was classified as inhomogeneous, homogeneous or node with an echo-rich centre. The first 
two classifications were considered potentially malignant and the last potentially benign. 
Subsequent histological examination of the axillary clearance specimens confirmed no false-
positive results. The more axillary lymph nodes detected by ultrasonography the higher the 
percentage of metastases. The incidence of lymph node involvement and the rate of detection 
of lymph nodes increased with increasing tumour size.  
In 36 per cent of all node positive operable breast cancer patients lymph node metastases 
were detected by ultrasonography and cytology. With this technique 17 percent of the patients 
do not need SN biopsy since ultrasonographically guided FNAC did already have detect 
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metastases and complete ALND can be performed as a primary procedure. These percentages 
are rather low probably due to a learning curve in recognising and aspirating lymph nodes 
with a suspicious image on ultrasound. 
 Keeping the learning curve in mind it was reasonable to predict an increased sensitivity of 
the ultrasound and FNAC after the initial study. Since a full ALND continued to be the 
standard treatment in node positive breast cancer patients the sensitivity and specificity of the 
combined procedure could be evaluated even after the implementation of the SN procedure. 
In CHAPTER 4 the results of this succeeding study is shown. Lymph node aspiration 
contained adequate material in 73 percent with a sensitivity of 57 percent and a specificity of 
96 percent in detecting metastases. Ultrasound-guided FNAC could identify 44 percent of 
histologically proven axillary metastases in primary breast cancer patients, 20 percent of the 
total patient population. In contrast of earlier results there were 3 false-positive results, 
explained by multifocality of the tumour associated with a dense lymphocytic infiltration, 
cytological misreading of cell groups and one is still unknown. 
Ultrasound and FNAC was able to identify 83 percent of the patients with 4 or more 
axillary lymph node metastases. Twenty-five percent of the patients with 1-3 positive axillary 
lymph nodes were found to contain micrometastases only. It is clear that neither ultrasound 
nor cytology can replace histology in the detection of these metastases, but it partly explains 
the relative low sensitivity in both the initial multicenter and the single institution succeeding 
study. It seems unlikely that with the present technique the sensitivity will increase further. 
 Naturally, more intensive analysis of lymph nodes with serial sectioning and 
immunohistochemistry will reveal more metastatic disease. Up until now the biological 
relevance of micrometastases detected by immunohistochemical staining only is unclear. It 
has been suggested that the SN may, in certain circumstances, be capable of controlling local 
disease by removing metastatic tumour cells. It is also speculated that isolated tumour cells 
may not have potential for outgrowth. This could explain that metastatic disease in non-
sentinel nodes only rarely occur in cases with micrometastasis. The term micrometastasis has 
only been defined arbitrarily, and its definition varies between studies. A cut off point of 2mm 
has been used in many studies and is included in the TNM classification. In CHAPTER 5 the 
incidence of metastases in non-SNs is described in case of a detected micrometastasis. The 
non-SNs were investigated like the SN; cut at 250 µm intervals, immunostained with 
anticytokeratin antibody CAM 5.2 using a standard peroxidase procedure in an automated 
immunostainer. Metastases in non-SNs were identified in 11 of 32 patients, five of whom had 
initially been diagnosed as not having non-SN metastases. In seven patients more than one 
node was involved and in four patients the non-SN metastasis was larger than the SN 
metastasis (including two patients with non-SN macrometastases). It was observed that     
non-SN metastases as clusters were associated with tumours > 2cm in size and with high-
grade tumours. The question arises whether the presence of microscopic tumour deposits in 
the SN justifies complete axillary clearance and adjuvant treatment. The answer hinge upon 
delineating the biological behaviour of small tumour deposits and small numbers of isolated 
tumour cells. A micrometastasis requires the arrest of tumour cells in the tissue and 
proliferation. Biological characteristics such as viability, angiogenic capacity, and avoidance 
of the host-immune reaction may be equally important factors. Whatever the outcome of 
single tumour cells in the circulation or in organs may be, it should be appreciated that the 
very fact that they are detected implies that access to the lymphatic or blood vessels has been 
gained, and that a line of defence has been breached in the metastatic pathway. On the basis of 
our findings we find it premature to conclude that ALND may be avoided in patients with T1-
2 tumours and SN micrometastases. 
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 As mentioned above the ultrasound guided FNAC is a reliable technique in the primary 
selection for a successful SN biopsy. However, the tracebility and sensitivity of the SN did 
not reach 100 percent in the initial multicenter study. In CHAPTER 6 causes of failure to 
trace the (“real”) SN in clinically node negative breast cancer patients with the primary 
tumour in situ are evaluated. After injection of 30-40MBq 99m-Technetium nanocolloid the 
SN was traced with guidance of a probe. The probe measured the radioactivity ratio (SN vs. 
background) in counts per second. Two levels of activity were distinguished; inadequate and 
adequate ratio. In case of inadequate ratio the sentinel node was not identified or only after a 
time consuming search. The number of involved lymph nodes after axillary dissection was 
classified according to the Dutch guidelines for adjuvant treatment in 1-3 and � 4 positive 
nodes.
 In the normal (non-metastatic) situation the radioactivity is bound to colloid and the colloid 
is phagocytosed by macrophages. However, if the SN is completely replaced by tumour-cells 
there is no healthy lymph tissue left to phagocytose the colloid and radioactivity. The colloid 
will skip the SN and be phagocytosed by another, non-sentinel, lymph node or will not be 
phagocytosed at all. This will result in a false-negative SN or non-detectable radioactive 
lymph nodes. 
This was the postulated hypothesis for the significant relationship between extend of nodal 
involvement in terms of extranodal growth (ENG) and/or total number of positive nodes and 
failure of the SN detection. 
 There was a significant influence of the number of positive nodes on the radioactive ratio 
(� 4 vs. 0-3 and � 4 vs. 1-3). In case of � 4 positive lymph nodes identification of the “real” 
SN failed in 67 percent. In 3/5 false negative SN patients the radioactive ratio was inadequate, 
all found to have � 4 involved nodes. The relation between ENG and the radioactive ratio was 
also significant (ENG vs. no metastases/no ENG and ENG vs. no ENG). The presence of 
ENG is in 72 percent responsible for failure of the identification of the “real” SN.
So the postulated hypothesis seems to be correct. In order to avoid failure preoperative 
ultrasound examination of the axilla in combination with FNAC is recommended. This 
technique is able to identify at least 62% of the patients with � 4 positive lymph nodes in the 
axilla.
 As mentioned in chapter 2 the co-ordinator was responsible for the implementation in the 
participating hospitals and involved departments. One of the responsibilities was to inform the 
involved staff about all aspects of the procedure. Because nuclear medicine was unknown 
territory for most persons concerned, one of the most frequently asked questions were about 
safety issues regarding the procedure. In CHAPTER 7 the results of measurements after the 
radiation dose are described and discussed.
Exposure to ionising radiation can be harmful and working with radioactivity has rigid 
rules. Dose limits are determined for three groups; exposed workers, workers and members of 
the public. Dose limits are prepared to prevent deterministic effects, such as, erythema, and 
stochastic effects such as cancer. Dose limits for deterministic effects are expressed in dose 
limits for hands, feet, ankles, forearms, skin and the eye lens. The maximum handdose for 
workers and exposed workers are 50 and 500 mSv/year respectively. Dose limits for 
stochastic effects are expressed in effective dose limits. The maximum effective dose for 
workers and exposed workers is 1 and 20 mSv/year respectively. 
 During the operation and the histologic examination the radiation dose to which the 
surgeon, the surgeon-assistant, the theatre nurse, the pathologist and the pathologist-assistant 
were exposed was measured. Small thermoluminoscentdosemeters were used on the thoracic 
wall, abdominal wall, left (non-dominant) and right (dominant) hand of the surgeon, the 
assistant-surgeon and the pathologist. Only the chest wall dose of the theatre nurse and the 
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pathologist-assistant was measured. The measurements on the theatre-nurse, the pathologist 
and the pathologist-assistant were beneath the detection level of 10 µSv. The highest 
measured doses are the hands of the surgeon and his assistant (17±61 mSv), however the dose 
limits for hands are higher than for other parts of the body.  
There was a difference between the exposure of the dominant- and non-dominant had of 
the surgeon caused by the operating technique. The non-dominant hand presents the tissue to 
be removed by the dominant hand, resulting in a shorter distance between non-dominant hand 
and radioactive tissue in comparison with the dominant hand. 
 Taking the dose limits into account the abdominal wall of the surgeon relatively receives 
the highest dose, with an average of 8.2 µSv per procedure. Within the Dutch statutory limits 
a surgeon could perform 100 sentinel node procedures a year (one-day procedure with 30MBq 
99m-Technetium). This means that in general there is no need for any concern about the 
safety of the procedure for health workers. 
 After the initial study the SN has proven to be a valuable tool in predicting the status of the 
axilla. The SN biopsy became routine practice despite lack of long-term follow-up results 
concerning local control and overall survival. In CHAPTER 8 the follow-up results of breast 
cancer patients with an internal mammary chain (IMC) hotspot on lymphoscintigraphy are 
discussed. The axillary lymph node status is one of the most important prognostic factors in 
predicting prognosis. However, dissemination of tumour cells through the lymph system is 
not only taking place to the axillary lymph nodes but also to the supraclavicular and internal 
mammary lymph nodes. In the study period the policy was not to explore the parasternal 
region even if the IMC hotspot was the only hotspot. This decision was based on studies 
reporting no survival benefit after complete dissection of the internal mammary lymph nodes 
1-3. In a 6.5 year period lymphoscintigraphy showed in 86 (15%) of 571 patients a hotspot in 
the IMC, in 64 of them the axillary SN was negative. In the literature the incidence of positive 
IMC with negative axillary lymph nodes is 0-10%. Based on tumour characteristics, adjuvant 
systemic therapy was not indicated in 25 of the 86 SN negative patients. Therefore, in case of 
a 10% incidence of positive IMC with negative axillary lymph nodes, routine IMC SN biopsy 
would only in 2-3 of the 571 patients have resulted in the single argument for adjuvant 
systemic therapy. In the follow-up (median 36 months) no parasternal recurrences were 
found. Because only very few patients would benefit in the sense of indication of systemic 
therapy and parasternal recurrences are rare, we maintained our policy not to explore the 
IMC.
 Three years after the SN biopsy became routine practice the first reports on axillary 
recurrences appeared. In CHAPTER 9 our 5-year follow up results are discussed. We 
evaluated the value of axillary ultrasound in combination with fine-needle aspiration cytology 
(FNAC) in the early detection of axillary recurrences and the incidence of axillary- and local 
recurrences. In the validation period the incidence of false-negative SNs was about 5%. 
Therefore a recurrence rate of 5% was expected. In a mean follow-up period of 65 months we 
observed 4 axillary recurrences (2.7 %) and 7 local recurrences in a group of 149 patients. 
None of the axillary recurrences was detected by ultrasound. Axillary recurrences were 
treated with full axillary lymph nodes dissection (ALND). Three of the four axillary 
recurrences were observed within the first 14 months after SN biopsy. Based on reported data 
on the incidence of axillary recurrences it can be concluded that the incidence after negative 
SN is much lower than expected. In the group of patients with local recurrence or ipsilateral 
second primary tumour, part of the treatment was in 6 out of 7 patients ALND. Pathological 
examination showed in 4 of these 6 patients axillary lymph node metastases. But it remains 
unclear if the metastases were from the primary tumour or recurrence.  We concluded that the 
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clinical relevant incidence of axillary recurrences after negative SN is much lower than 
expected. Up until now treatment of axillary recurrences is ALND, the place of re-SN is 
uncertain. There is no value of axillary ultrasound and FNAC in the routine follow-up and 
most cases are detected within one and a half-year after the primary procedure.  
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 In de afgelopen jaren is de behandeling van borstkanker veranderd naar een minder 
ingrijpende en mutilerende ingreep. Borstbesparende behandeling en de introductie van de 
schildwachtklier (SWK) procedure zijn de twee belangrijkste veranderingen. De introductie 
van een nieuwe techniek kost echter tijd. De eerste stap is ontwikkeling en evaluatie. Indien 
de nieuwe techniek beter lijkt dan de standaard behandeling wordt een gerandomiseerde 
studie ter bevestiging opgezet en bij positief resultaat komt het ter beschikking van de 
betrokken patiëntengroep. In HOOFDSTUK 2 wordt de introductie van de SWK procedure 
in 3 deelnemende ziekenhuizen beschreven (een groot opleidingsziekenhuis, een oncologie-
centrum en een universitair ziekenhuis). Speciale aandacht werd gegeven aan de rol van de 
coördinatrice ter bewaking van de standaardisatie en kwaliteitscontrole binnen deze multi-
centrische studie. De rol van de coördinatrice was tweevoudig: allereerst begeleiding van de 
betrokken afdelingen bij de invoering en daarna (waarnodig) bijstellen van de procedure. 
Tijdens de onderzoeksperiode werden enkele aspecten van de procedure bijgesteld: de 
concentratie van het colloïd in de radioactieve oplossing, intracutane injectie van de blauwe 
inkt na teleurstellende resultaten van de peritumorale injectietechniek, injectie craniaal van 
het litteken in plaats van caudaal. Met deze veranderingen werden de resultaten uitstekend. 
Aan het eind van de studie periode waren de resultaten (sensitiviteit en fout-negativiteit) in de 
deelnemende ziekenhuizen gelijk. 
 Naar aanleiding van deze resultaten werd een implementatietraject gestart met hulp van 
het Integraal Kankercentrum Rotterdam. De regionale ziekenhuizen die de SWK procedure 
wilden invoeren werd een leerfase van 50 patiënten aangeraden waarbij een “dubbel 
procedure” werd uitgevoerd (SWK en okselklierdissectie (OKD)). Indien er sprake was van 
minder dan 5% fout-negativiteit kon volstaan worden met verwijderen van alleen de SWK, 
alle patiënten werden centraal geregistreerd en adequaat vervolgd. Speciale aandacht werd 
gegeven aan echografie van de oksel tijdens de follow-up in de hoop regionale recidieven zo 
spoedig mogelijk op te sporen. 
 De SWK procedure is gecompliceerd en tijdrovend. Het heeft enkele nadelen zoals een 
laag identificatiepercentage bij veel uitzaaiingen in de lymfklieren van de oksel, fout-
negatieve resultaten, benodigde radioactiviteit en pathologisch onderzoek met behulp van de 
vriescoupe techniek. Vanwege deze nadelen zou vervanging van de SWK procedure door 
eenvoudigere methoden nuttig zijn. In een studie voorafgaand aan het SWK tijdperk bleek 
echografisch onderzoek van de oksel in combinatie met cytologisch punctie een onderzoek te 
zijn met een lage sensitiviteit maar met een specificiteit van 100%. Vanwege dit resultaat 
maakte dit onderzoek deel uit van de SWK procedure in een multicentische studie naar de 
waarde van de SWK biopsie bij klinisch okselklier-negatieve borstkanker patiënten. Indien 
uitzaaiingen in de oksel werden vastgesteld was de SWK niet meer relevant. 
 In HOOFDSTUK 3 worden de resultaten van de echografie en cytologische punctie 
besproken. Het echopatroon werd beoordeeld als inhomogeen, homogeen of echo-rijk 
centrum. De eerste twee werden als potentieel maligne beschouwd en de laatste als potentieel 
benigne. Pathologisch onderzoek van het OKD preparaat toonde geen fout-positieve 
resultaten. Des te meer lymfklieren echografisch werden geïdentificeerd des te hoger de kans 
op uitzaaiingen. De incidentie van uitzaaiingen nam ook toe bij toenemende tumorgrootte. 
Bij 36% van alle lymfklier-positieve operabele borstkanker patiënten werden uitzaaiingen 
geconstateerd door middel van echografie gecombineerd met cytologie. Door deze techniek 
heeft 17% van alle borstkanker patiënten geen SWK procedure nodig en kan een OKD 
plaatsvinden als initiële behandeling. Deze percentages zijn enigszins laag, vermoedelijk ten 
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gevolge van de leercurve in de herkenning en aanprikken van lymfklieren met een verdacht 
echografisch beeld. 
 Rekening houdend met de leercurve leek het logisch dat de sensitiviteit van de echografie 
en cytologische punctie zou toenemen na de initiële studie. Aangezien verwijdering van alle 
lymfklieren in de oksel de standaard behandeling bleef bij lymfklier-positieve borstkanker 
patiënten kon de sensitiviteit en specificiteit van de gecombineerde procedure ook na de 
invoering van de schildwachtklier worden geëvalueerd. In HOOFDSTUK 4 worden de 
resultaten van de vervolg studie besproken. Bij punctie van een lymfklier was er in 73% 
voldoende materiaal voor diagnostiek, de sensitiviteit voor het aantonen van uitzaaiingen was 
57% met een specificiteit van 96%. Echografie met cytologie was in staat om 44% van de 
patiënten met een histologisch bewezen uitzaaiing in een lymfklier in de oksel te 
identificeren, dat is 20% van de gehele patiënten populatie. In tegenstelling tot eerdere 
resultaten waren er 3 fout-positieve uitslagen, te verklaren door multifocaliteit van de tumor 
geassocieerd met een dicht lymfogene infiltratie, cytologische misinterpretatie van groepen 
cellen en een niet-bekende oorzaak. Echografie en cytologie waren in staat om 83% van de 
vrouwen met 4 of meer uitzaaiingen in de okselklieren aan te tonen. Vijfentwintig procent van 
de patiënten met 1-3 positieve okselklieren bleken alleen micro-uitzaaiingen te bevatten. Het 
is duidelijk dat nòg echografie nòg cytologie histologie kan vervangen in de opsporing van 
deze uitzaaiingen, maar het verklaart deels de relatieve lage sensitiviteit in zowel het initiële 
multicentrische studie als de vervolg studie die plaatsvond in 1 ziekenhuis. Het lijkt niet 
aannemelijk dat met de huidige techniek de sensitiviteit verder zal toenemen. 
 Uiteraard levert meer intensieve onderzoeksmethode van de lymfklieren met sprongserie 
en immunohistochemie een hoger percentage uitzaaiingen op. Tot op dit moment is het 
biologische karakter van micro-uitzaaiingen, gevonden met immunohistochemische kleuring, 
niet duidelijk. Er wordt gesuggereerd dat de SWK soms in staat is lokale ziekte te controleren 
door verwijdering van uitgezaaide tumorcellen. Er wordt ook gesuggereerd dat geïsoleerde 
tumorcellen niet de capaciteit zouden hebben om verder uit te groeien. Dit zou kunnen 
verklaren dat uitgezaaide ziekte in niet-SWKs nauwelijks voorkomt in geval van micro-
uitzaaiingen. De definitie van de term micro-uitzaaiing is arbitrair en varieert tussen diverse 
studies. Een cut-off point van 2mm wordt gebruikt in diverse studies en is geïncludeerd in de 
TNM classificatie. In HOOFDSTUK 5 wordt de incidentie van uitzaaiingen in niet-SWKs bij 
een micro-uitzaaiing in de SWK besproken. De niet-SWKs werden onderzocht conform de 
SWK; gesneden om de 250m, immunohistochemische kleuring met anticytokeratine 
antilichaam CAM 5.2 gebruik makend van een standaard peroxidase procedure in een 
immunokleurder. Uitzaaiingen in niet-SWKs werden gevonden bij 11 van de 32 patiënten, 
waarbij 5 patiënten initieel als vrij van uitzaaiingen in de niet-SWKs waren geclassificeerd. 
Bij 7 patiënten ging het om meer dan 1 lymfklier en in 4 patiënten was de uitzaaiing in de 
niet-SWK groter dan in de SWK (inclusief 2 patiënten met niet-SWK macro-uitzaaiingen). Er 
werd gevonden dat uitzaaiingen in de niet-SWK als clusters samen ging met tumoren > 2cm 
en met hoog-gradige tumoren. De vraag rijst of  bij geïsoleerde tumorcellen in de SWK een 
OKD en adjuvante behandeling noodzakelijk is. Het antwoord hangt af van het biologische 
gedrag van kleine tumorcelgroepjes en geïsoleerde tumorcellen. Voor de vorming van een 
micro-uitzaaiing is hechting in weefsel en deling noodzakelijk. Biologische kenmerken zoals 
levensvatbaarheid, angiogene capaciteit en vermijden van de gastheer immuun respons 
zouden even belangrijke factoren kunnen zijn. Wat het gevolg van enkele tumorcellen in de 
circulatie of in organen ook is, het feit dat ze gevonden zijn duidt erop dat er toegang is tot het 
lymfatisch systeem of bloedvaten en dat een verdedigingslijn doorbroken is. Op basis van 
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onze resultaten vinden we het te vroeg om te concluderen dat een OKD vermeden kan worden 
bij patiënten met een T1-2 tumor en een micro-uitzaaiing in de SWK. 
 Zoals boven vermeldt is de echografie in combinatie met cytologische punctie bij de 
primaire selectie voor een succesvolle SWK biopsie. Echter, er was geen 100% opsporing en 
sensitiviteit in de initiële multicentrische studie. In HOOFDSTUK 6 worden de oorzaken van 
falen in het opsporen van de “echte” SWK bij klinisch okselklier negatieve borstkanker 
patiënten met de primaire tumor in situ besproken. Na injectie van 30-40 MBq 99m-
Technetium  nanocolloid werd de SWK opgespoord met behulp van een probe. De probe meet 
de radioactiviteits ratio (SWK vs achtergrond) in counts per seconde. Twee activiteitsniveaus 
werden onderscheiden; onvoldoende en voldoende. In geval van een onvoldoende ratio was 
de SWK niet geïdentificeerd of slechts na lange tijd. Het aantal uitzaaiingen in de lymfklieren 
in de oksel werd ingedeeld conform de Nederlandse Richtlijnen voor adjuvante behandeling 
in 1-3 en � 4 positieve lymfklieren in de oksel. In de normale (niet-uitgezaaide) situatie wordt 
de radioactiviteit gebonden aan het colloïd en het colloïd wordt opgenomen door macrofagen. 
Echter, indien de SWK volledig wordt ingenomen door tumorcellen dan is er geen gezond 
lymfklierweefsel meer om het colloïd en radioactiviteit op te nemen. Het colloïd slaat de 
SWK over en wordt opgenomen door een andere, niet-SWK, lymfklier of wordt niet 
opgenomen. Dit resulteert in een fout-negatieve SWK of in niet op te sporen radioactieve 
lymfklieren. 
 Dit was onze hypothese voor de significante relatie tussen uitgebreide aantasting van 
lymfklieren in de oksel, in termen als extranodale groei (ENG) en/of aantal positieve 
lymfklieren en het falen van de SWK opsporing. Er was een significante invloed van het 
aantal positieve okselklieren op de radioactiviteits ratio (� 4 vs 0-3 en � 4 vs 1-3). In het geval 
van � 4 positieve lymfklieren in de oksel faalde de identificatie van de SWK opsporing of was 
de radioactiviteits ratio onvoldoende in 67%. Bij 3 van de 5 fout-negatieve SWKs was de 
radioactiviteits ratio onvoldoende, allen bleken � 4 aangetaste lymfklieren te hebben. De 
relatie tussen ENG en de radioactiviteits ratio is eveneens significant (ENG vs geen 
uitzaaiingen/geen-ENG en ENG vs geen-ENG). De aanwezigheid van ENG is 
verantwoordelijk voor het falen van de SWK identificatie of onvoldoende ratio in 72%. Het 
lijkt er dus op dat onze geformuleerde hypothese correct is.  
 In een poging om falen te vermijden wordt preoperatief uitgevoerde echografie van de 
oksel in combinatie met cytologische punctie aangeraden. Deze techniek is in staat om 
tenminste 62% van de vrouwen met � 4 positieve lymfklieren in de oksel te identificeren. 
 Zoals in hoofdstuk 2 vermeld was de coördinatrice verantwoordelijk voor de 
implementatie in de deelnemende ziekenhuizen en betrokken afdelingen. Eén van de 
verantwoordelijkheden was de betrokken personen te informeren over alle aspecten van de 
procedure. Aangezien nucleaire geneeskunde onbekend terrein was voor de meeste betrokken 
personen, betrof de meest gestelde vraag het veiligheidsaspect. In HOOFDSTUK 7 worden 
de resultaten van de metingen naar de stralingsdosis beschreven en geëvalueerd. Blootstelling 
aan straling kan schadelijk zijn en het werken ermee gaat gepaard met strenge regels. Dosis 
limieten zijn vastgesteld voor drie groepen; blootgestelde werknemers, werknemers en de 
bevolking. Dosis limieten zijn vastgesteld om deterministische effecten, zoals erytheem, en 
stochastische effecten, zoals kanker, te voorkomen. Dosis limieten voor deterministische 
effecten worden uitgedrukt in dosis limieten voor handen, voeten, enkels, onderarmen, huid 
en lenzen. De maximale handdosis voor werknemers en blootgestelde werknemers zijn 
respectievelijk 50 en 500 mSv/jaar. Dosis limieten voor stochastische effecten worden 
uitgedrukt in effectieve dosis limieten. De maximale effectieve dosis voor werknemers en 
blootgestelde werknemers zijn respectievelijk 1 en 20 mSv/jaar. Tijdens de operatie en het 
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histologisch onderzoek werd de stralingsdosis gemeten waaraan de chirurg, de assistent van 
de chirurg, de operatiekamerassistente, de patholoog en de assistent van de patholoog werden 
blootgesteld. Kleine thermoluminiscent dosismeters werden gebruikt op de borst, buik, linker 
(niet-dominante) en rechter (dominante) hand van de chirurg, de assistent van de chirurg en de 
patholoog. Van de operatiekamerassistente en de assistent van de patholoog werd alleen de 
dosis op de borst gemeten. De metingen bij de operatiekamerassistent, de patholoog en diens 
assistent waren alleen beneden het detectieniveau van 10Sv. De handen van de chirurg en 
diens assistent kregen de hoogst gemeten dosiswaarden (17 ± 61mSv), de dosislimiet voor 
handen is echter hoger dan voor andere delen van het lichaam. Er was een verschil in 
blootstelling van de dominante en niet-dominante hand van de chirurg veroorzaakt door de 
operatietechniek. De niet-dominante hand presenteert het door de dominante hand te 
verwijderen weefsel, dit resulteert in een kortere afstand tussen niet-dominante hand en het 
radioactieve weefsel in vergelijking tot de dominante hand. 
 Rekening houdend met de dosislimieten ontvangt de buik van de chirurg relatief de 
hoogste dosis met een gemiddelde van 8.2Sv per procedure. Binnen de Nederlandse 
regelwetgeving mag een chirurg 100 SWK procedures uitvoeren (een-dags procedure met 
30MBq 99m-Tc). Dit betekent dat er geen reden is tot ongerustheid betreffende de veiligheid 
van de procedure voor medewerkers in de zorg. 
 Na de initiële studie heeft de SWK bewezen van waarde te zijn in het voorspellen van de 
okselklierstatus. De SWK biopsie werd routine ondanks het ontbreken van follow-up 
resultaten betreffende lokale controle en overleving. In HOOFDSTUK 8 worden de follow-
up resultaten besproken van borstkanker patiënten met een hotspot op de lymfoscintigrafie ter 
plaatse van de parasternale klierketen (PSK). De axillaire lymfklier status is een van de meest 
belangrijke prognostische factoren bij het voorspellen van de prognose. Echter, verspreiding 
van tumorcellen door het lymfe systeem vindt niet alleen plaats naar de axillaire lymfklieren 
maar ook naar de supraclaviculaire en parasternale lymfklieren. Tijdens de studieperiode was 
het beleid dat hotspots ter plaatse van de PSK ongemoeid werden gelaten zelfs als dat de 
enige hotspot was. Deze beslissing was gebaseerd op studies waarin geen overlevingswinst 
werd beschreven na complete dissectie van de parasternale lymfklieren 1-3 . In 6.5 jaar toonde 
de lymfoscintigrafie bij 86 (15%) van de 571 patiënten een hotspot ter plaatse van de PSK. Bij 
64 van hen was de axillaire SWK negatief. In de literatuur is de incidentie van positieve PSK 
met negatieve axillaire lymfklieren 0-10%. Gebaseerd op tumorkenmerken was aanvullende 
systemische behandeling niet geïndiceerd bij 25 van de 86 SWK negatieve patiënten. In het 
geval van een incidentie van 10% positieve PSK bij negatieve axillaire lymfklieren, dan zou 
het standaard verwijderen van de PSK schildwachtklier bij slechts 2-3 van de 571 patiënten 
hebben geleid tot een argument voor systemische behandeling. Gedurende de follow-up 
(mediaan 36 maanden) is er bij geen patiënt een parasternaal recidief gevonden. Aangezien 
slecht een enkele patiënt voordeel zou kunnen hebben, in de zin van een indicatie voor 
systemische behandeling, en parasternale recidieven slechts sporadisch voorkomen is het 
beleid gehandhaafd om de PSK ongemoeid te laten. 
 Drie jaar nadat de SWK procedure standaard behandeling werd, kwamen de eerste 
artikelen over axillaire recidieven. In HOOFDSTUK 9 worden onze 5-jaars follow-up 
resultaten besproken. We bekeken de waarde van echografie van de oksel in combinatie met 
cytologie in de vroege detectie van axillaire recidieven èn de incidentie van axillaire- en 
lokale recidieven. Tijdens de validatie periode was de incidentie van een fout-negatieve SWK 
circa 5%. Daardoor werd een recidief percentage van 5% verwacht. Tijdens de gemiddelde 
follow-up periode van 65 maanden zagen we in 4 axillaire recidieven (2.7%) en 7 lokale 
recidieven bij een groep van 149 patiënten. Geen enkel axillair recidief werd gevonden door 
Samenvatting 
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de echografie. Axillaire recidieven werd behandeld met een volledig OKD. Drie van de vier 
recidieven werden binnen de eerste 14 maanden na de SWK procedure ontdekt. Gebaseerd op 
de gerapporteerde incidentie van axillaire recidieven mag geconcludeerd worden dat de 
incidentie van axillaire recidieven na een negatieve SWK veel lager is dan verwacht.  
 In de groep patiënten met een lokaal recidief of ipsilaterale secundaire tumor bestond bij 6 
van de 7 patiënten de behandeling onder andere uit een OKD. Pathologisch onderzoek toonde 
bij 4 van deze 6 patiënten uitzaaiingen in de okselklieren. Maar het blijft onduidelijk of de 
uitzaaiingen van de primaire tumor of van het recidief zijn.  
 We concludeerden dat de klinisch relevante incidentie van axillaire recidieven na een 
negatieve SWK veel lager is dan men verwachtte. Tot op heden is de behandeling een OKD, 
de plaats van een re-SWK procedure is onduidelijk. In de routine follow-up heeft een 
echografie van de oksel geen waarde en de meeste gevallen werden binnen anderhalf jaar na 
de primaire procedure ontdekt. 
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 Our current recommendation for staging clinically node negative breast cancer patients 
involves sentinel node staging after ultrasound of the axilla as this non-invasive procedure has 
been demonstrated by us to limit the requirement for SN staging. The histopathologic work up 
of the SN involves step sectioning and the use of immunohistochemistry for the identification 
of micrometastases. A full axillary lymph node dissection is recommended for patients with 
involved sentinel nodes (micrometastases > .2 mm) and is not necessary for patients without 
sentinel node involvement. We are not of the opinion that sentinel node staging of the internal 
mammary chain is useful.  
 We consider this recommendation a recommendation as a temporary one as the 
management of breast cancer patients is changing every 5-10 years and the impact of 
molecular staging, gene-profiling of primary tumours, new developments in imaging 
modalities, new drugs and developments in cancer prevention will change the current 
recommendations over the years to come. 
 Several important questions remain for the coming period and will be discussed her within 
the context of the recent literature:  
- What is the relevance of micrometastases? Is size of the micrometastases relevant 
(isolated tumour cells versus 0,2mm versus 2 mm) in terms of prognosis, need for full 
axillary lymph node dissection etc. 
- What is the need for a full axillary dissection in case of (any) positive (sentinel) lymph 
nodes.
- Which technique is able to reduce the number of sentinel node procedures? It is clear 
that even very sophisticated imaging will not be able to detect these smallest 
metastases. For this purpose the SN procedure will remain the staging procedure of 
choice. However, the range between macro metastases discovered by US and FNA and 
these very small metastases is large and every non-invasive technique to identify a 
higher percentage of these metastases will be worthwhile. Which technique is able to 
reduce the number of sentinel node procedures?  
- What will be the new more powerful prognostic indicators in state lymph node 
metastases will they make SN-staging redundant? 
Clinical relevance of micro-metastases 
 Traditionally the pathological examination of axillary lymph nodes consisted of 
hematoxylin and eosin (H&E) staining of only one or a few sections. A false negative result is 
possible and related to the size of the node, the orientation of the node in the sectioning block, 
the size and location of any metastases within the node and the number of sections examined1.
With the introduction of the sentinel node biopsy the pathological examination of the 
(sentinel) node has become more extensive. The sentinel node was examined with serial or 
step sectioning and immunohistochemical (IHC) staining in case of negative H&E. This 
combination is a more sensitive method of detecting tumour cells and therefore results in 9-
47% upstaging 2-5. Many of these metastases detected by immunohistochemistry are micro-
metastases or isolated tumour cells. In the new TNM classification a distinction is made 
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between macro-metastasis (>2mm), micro-metastasis (0.2-2.0mm) and isolated tumour-cells 
(≤0.2mm) 6.
 The clinical relevance of isolated tumour cells or micro-metastases is unclear since we do 
not know if these cells are capable of further growth and dissemination. The relevance of 
answering this question is related to the benefit in survival for N0 versus isolated tumour cells 
(pN0i+) or micro-metastasis (pN1mi), also taking into account tumour characteristics.  
Before the sentinel node era, several studies determined the influence of metastases ≤2mm on 
survival. Especially the latter studies could identify a significance survival difference between 
patients with metastases ≤2mm and >2mm. Up until now there was no significant difference 
between N0 and N+ ≤2mm. Again, all studies were based on analysis of axillary lymph node 
specimens (as opposed to sentinel node specimens) 7-10.
 The introduction of the sentinel node technique has created a useful tool for further study 
of micrometastatic disease. The first studies based in sentinel node specimens show similar to 
the old studies no significant survival difference between N0 and N0i+ or N1mi 11, 12. Possible 
explanations are small numbers of patients, relatively short follow-up and enlargement of 
adjuvant treatment indications based on tumour characteristics. The American College of 
Surgeons Oncology Group trial Z0010 and NSABP B-32 study will study the detection of 
small foci or even single metastatic cells in the sentinel node by the use of serial sectioning, 
IHC, and molecular techniques, like reverse transcriptase-polymerase chain reaction analysis. 
This large data set will try to answer the effect on a difference in survival or that there is no 
real biologic significance of these findings. 
 In conclusion, identification of isolated tumour cell clusters may not be identifying a group 
of patients with outcome worse than node-negative patients. The definition before the era of 
the sentinel node biopsy of 2.0mm for clinically significant metastases may not be far from 
the new reality. Definitive therapeutic recommendations await the results of ongoing 
multicentre trials 
Preoperative staging of clinically node negative breast cancer patients 
CT and MRI
 Both CT (computed tomography) and MRI (magnetic resonance imaging) are cross-
sectional imaging methods that produce high-quality images of the axilla. Few studies have 
been published on this subject, but the latest have shown high sensitivity and specificity (CT 
93% and 82% respectively and MRI 90% and 82% respectively), although, both CT and MRI 
are restricted to imaging only. The detection of micro-metastases and small tumour-infiltrated 
lymph nodes is limited by the currently achievable spatial resolution and make these 
modalities no superior to sentinel node procedure 13.
PET
 Several clinical studies have been carried out to evaluate the accuracy of PET in the 
axillary staging of operable primary breast cancer. Reported sensitivities range from 20-100% 
and specificity’s from 66-100%. These studies have sometimes provided conflicting results, 
either supporting the possibility of using PET to select patients who need axillary dissection 
or questioning whether PET can accurately assess the axillary status in primary breast cancer. 
The performance of PET depends on primary tumour load and the axillary tumour load so the 
limitation of PET is in the detection of micro-metastases. The added value offered by PET in 
comparison with sentinel node biopsy and ultrasound in combination with FNAC lies in the 
fact that PET is a non-invasive procedure that allows the biological characterisation of breast 
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cancer and viewing of the entire body. But PET is based on the present literature not superior 
14-16.
PET/CT
 Combined PET/CT systems have recently been developed and allow functional PET and 
anatomical CT images to be acquired in one session and rapidly co-registered. The few 
published studies suggest that PET/CT diagnosis of both primary tumour and axillary lymph 
node involvement was more accurate than diagnosis using mammography, ultrasound or PET 
alone. A possible role of PET/CT is in the detection of parasternal metastases 17, 18.
MRI uspio
 In the last decade the MRI uspio was developed. Dextran-coated ultrasmall 
superparamagnetic iron oxide (USPIO) remains after intravenous injection in the intravascular 
compartment and is eventually incorporated into the reticulo-endothelial system and 
providing information on lymph node morphology. There is only one published article 
evaluating the value of uspio-enhanced MRI imaging for preoperative axillary lymph node 
staging in patients with breast cancer. Michel et al found a sensitivity of 82% with a 
specificity of 100%. If these preliminary results are confirmed in subsequent studies it could 
be a valuable pre-operative selecting examination. However, ultrasound in combination with 
FNAC is much more cost-effective than this new technique 19.
 In conclusion, at this time there is no accurate test that can replace sentinel node biopsy. 
Especially due to the absence of cytology or histology even more than micro-metastases will 
be missed.  
The need for a full axillary dissection in case of positive sentinel lymph nodes. 
 The immediate risk of leaving residual disease in the axilla when one sentinel node is 
positive ranges from about 10-40%, depending on the size of the primary tumour and the size 
of de metastasis in the sentinel node. When the metastasis found in the sentinel node is a 
cluster no greater than 0.2mm in size, detected only with immunohistochemistry, the risk of 
finding additional metastatic nodes is exceedingly rare 20, 21. Isolated tumour cells in the 
sentinel node with non-sentinel node involvement could be the result of failure to detect the 
true sentinel node caused by obstruction by metastasis. Preoperative ultrasound with FNA and 
intra-operative palpation of the axilla may prevent the chance of leaving massive metastatic 
tumour load in the axilla.
 It is important to note that the immediate risk of leaving residual disease in the axilla does 
not equate to always leaving this disease as untreated. The use of systemic adjuvant treatment 
and, in case of breast conserving therapy, the use of tangential radiation fields may result in 
effective treatment of residual (microscopic) axillary nodal disease 22-25. This hypothesis is 
currently tested in a randomised EORTC trial. In this “AMAROS” trial breast cancer patients 
with tumours over 5mm and less than 3cm and a positive sentinel node are randomised 
between complete axillary lymph node dissection and radiotherapy to the axilla. Next 
question is whether delayed treatment of residual disease worsens overall survival. The 
preliminary results of the follow up of sentinel node negative patients with axillary recurrence 
show no statistically significant differences in local control and survival between initially 
sentinel node positive patients and secondary node positive patients. 
Again, definitive therapeutic recommendations await the results of ongoing multicentre trials. 
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 Prognostic markers in breast cancer patients 
 The recognition of women who are at risk of relapse later is extremely important. In the 
near past a positive lymph node status was the most important indication for adjuvant 
treatment. The beneficial effects of adjuvant systemic treatment in these patients have been 
repeatedly shown in prospective randomised trials. However, these therapeutic effects have 
considerable side effects and not all patients benefit from this toxic treatment 26. But even in 
lymph node negative patients relapse occurred in 20-30% 27. It would be of immense clinical 
value if this high-risk group could be identified by the use of prognostic factors. Most of these 
factors are determined by identifying certain characteristics of the tumour such as size, grade, 
histology, receptor status, lymphatic and vascular invasion. Because of the ability of 
identifying high-risk characteristics, lymph node status was no longer the only adjuvant 
treatment indication. In the last decade the development of predictive models has accelerated. 
Her2-neu receptor and gene-expression profiling are the most promising 28-30.
 If the development of gene-expression profiling continues the role of the sentinel node 
biopsy will become more and more less. It is questionable if in node positive patients full 
axillary lymph node dissection is still necessary for local control and to identify candidates for 
adjuvant radiotherapy. 
 It is possible that control of a large axillary tumour load by either surgery or radiotherapy 
will still be important but non-invasive procedures like ultrasound in combination with fine 
needle aspiration are able to identify most of these patients. Small metastases will be missed 
by this procedure but delayed treatment in case of local failure seems to do no harm on overall 
survival.
 In conclusion: the sentinel node plays a significant role in the evolution of breast cancer 
treatment but is likely that finally its prognostic role will be replaced by combination of 
primary tumour characteristics and non-invasive staging procedures of the axilla. 
Literature
1. Wilkinson EJ, Hause L. Probability in lymph node sectioning. Cancer 1974; 33:1269-74. 
2. Freneaux P, Nos C, Vincent-Salomon A, et al. Histological detection of minimal metastatic 
involvement in axillary sentinel nodes: a rational basis for a sensitive methodology usable in daily 
practice. Mod Pathol 2002; 15:641-6. 
3. Cserni G. Complete sectioning of axillary sentinel nodes in patients with breast cancer. Analysis of two 
different step sectioning and immunohistochemistry protocols in 246 patients. J Clin Pathol 2002; 
55:926-31. 
4. Dowlatshahi K, Fan M, Anderson JM, Bloom KJ. Occult metastases in sentinel nodes of 200 patients 
with operable breast cancer. Ann Surg Oncol 2001; 8:675-81. 
5. Torrenga H, Rahusen FD, Meijer S, Borgstein PJ, van Diest PJ. Sentinel node investigation in breast 
cancer: detailed analysis of the yield from step sectioning and immunohistochemistry. J Clin Pathol 
2001; 54:550-2. 
6. Sobin LH, Wittekind C. TNM Classification of malignant tumours: John Wiley & sons, 2002. 
7. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. International 
(Ludwig) Breast Cancer Study Group. Lancet 1990; 335:1565-8. 
8. Cote RJ, Peterson HF, Chaiwun B, et al. Role of immunohistochemical detection of lymph-node 
metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 1999; 
354:896-900. 
9. Nasser IA, Lee AK, Bosari S, Saganich R, Heatley G, Silverman ML. Occult axillary lymph node 
metastases in "node-negative" breast carcinoma. Hum Pathol 1993; 24:950-7. 
10. Friedman S, Bertin F, Mouriesse H, et al. Importance of tumor cells in axillary node sinus margins 




11. Chagpar A, Middleton LP, Sahin AA, et al. Clinical outcome of patients with lymph node-negative 
breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. 
Cancer 2005; 103:1581-6. 
12. Hansen NM, Grube BJ, Te W, Brennan ML, Turner R, Giuliano AE. Clinical significance of axillary 
micrometastases in breast cancer: how small is too small. Proc Am Soc Clin Oncol 2001; 20:91a. 
13. Lernevall A. Imaging of axillary lymph nodes. Acta Oncol 2000; 39:277-81. 
14. Crippa F, Gerali A, Alessi A, Agresti R, Bombardieri E. FDG-PET for axillary lymph node staging in 
primary breast cancer. Eur J Nucl Med Mol Imaging 2004; 31 Suppl 1:S97-102. 
15. van der Hoeven JJ, Hoekstra OS, Comans EF, et al. Determinants of diagnostic performance of [F-
18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg 
2002; 236:619-24. 
16. Byrne AM, Hill AD, Skehan SJ, McDermott EW, O'Higgins NJ. Positron emission tomography in the 
staging and management of breast cancer. Br J Surg 2004; 91:1398-409. 
17. Wang Y, Yu J, Liu J, Tong Z, Sun X, Yang G. PET-CT in the diagnosis of both primary breast cancer 
and axillary lymph node metastasis: initial experience. Int J Radiat Oncol Biol Phys 2003; 57:S362-
S363.
18. Zangheri B, Messa C, Picchio M, Gianolli L, Landoni C, Fazio F. PET/CT and breast cancer. Eur J 
Nucl Med Mol Imaging 2004; 31 Suppl 1:S135-42. 
19. Michel SC, Keller TM, Frohlich JM, et al. Preoperative breast cancer staging: MR imaging of the axilla 
with ultrasmall superparamagnetic iron oxide enhancement. Radiology 2002; 225:527-36. 
20. Hwang RF, Krishnamurthy S, Hunt KK, et al. Clinicopathologic factors predicting involvement of 
nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol 2003; 10:248-54. 
21. Van Zee KJ, Manasseh DM, Bevilacqua JL, et al. A nomogram for predicting the likelihood of 
additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg 
Oncol 2003; 10:1140-51. 
22. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised 
trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer 
Trialists' Collaborative Group. Lancet 1992; 339:71-85. 
23. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' 
Collaborative Group. Lancet 1998; 351:1451-67. 
24. Rouzier R, Extra JM, Klijanienko J, et al. Incidence and prognostic significance of complete axillary 
downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and 
cytologically proven axillary metastatic lymph nodes. J Clin Oncol 2002; 20:1304-10. 
25. Smidt ML, Janssen CM, Kuster DM, Bruggink ED, Strobbe LJ. Axillary recurrence after a negative 
sentinel node biopsy for breast cancer: incidence and clinical significance. Ann Surg Oncol 2005; 
12:29-33. 
26. Nieboer P, Buijs C, Rodenhuis S, et al. Fatigue and relating factors in high-risk breast cancer patients 
treated with adjuvant standard or high-dose chemotherapy: a longitudinal study. J Clin Oncol 2005; 
23:8296-304. 
27. Rosen PP, Saigo PE, Braun DW, Jr., Weathers E, DePalo A. Predictors of recurrence in stage I 
(T1N0M0) breast carcinoma. Ann Surg 1981; 193:15-25. 
28. Klijn JG, de Vries EG. [The value of gene expression profiles using micoarrays for the individualisation 
of adjuvant therapy after surgery for breast cancer]. Ned Tijdschr Geneeskd 2005; 149:618-22. 
29. van de Vijver M. Gene-expression profiling and the future of adjuvant therapy. Oncologist 2005; 10 
Suppl 2:30-4. 
30. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab 





Naam       : Antoinette Yda de Kanter 
Geboortedatum en –plaats : 29 augustus 1969 te Rotterdam 
Burgelijke staat    : Gehuwd met Marcel Verbeek 
            Moeder van Kiki Carolien en Huib Pieter 
Mrt ’06 – heden:   Radiotherapeut-Oncoloog  Centrale Bestralings Afdeling den Haag 
Juli’01 - mrt ’06:  Opleiding tot Radiotherapeut-Oncoloog Erasmus MC,       
        opleider prof. dr. P.C. Levendag 
Sept ’00 – juli ’01:  AGNIO Radiotherapie Erasmus MC 
Mrt ’99 – sept ’00:  AGNIO Chirurgie St Fransiscus Gasthuis te Rotterdam 
Jan – mrt ’99:   Projectmedewerkster van het Integraal Kankercentrum Rotterdam.   
       Projecten:   
- Implementatie van de sentinel node procedure in de regio Rotterdam 
- Oorzaken van post operatie mortaliteit bij colorectale tumoren 
’96 - ’98 :     Studiebegeleidster van het onderzoek naar de sensitiviteit en     
       specificiteit van de sentinel node biopsie bij operabele       
       mammacarcinoompatiënten.  
      
mei ’96:     artsexamen       
’94:      Afstudeeronderzoek afdeling Kinderoncologie, Erasmus MC / Sophia  
         Onderwerp: De groei bij kinderen met een rhabdomyosarcoom. 
    
’88 - ’94 :    Geneeskunde aan de Erasmus Universiteit Rotterdam  
           Doctoraal examen: mei ’94 






Het is zover, het boek is af. Bij het tot stand komen ervan hebben velen een belangrijke rol 
gespeeld. Enkele wil ik in het bijzonder bedanken. 
Mijn promotoren, Prof.dr. T. Wiggers en Prof.dr. A.M.M. Eggermont. Theo, met veel plezier 
denk ik terug aan de brainstorm sessies op de Heemraadsingel. Daar is de basis van dit 
proefschrift gelegd. Gelukkig bleek het een stevige basis te zijn want er moesten op weg naar 
deze promotie vele hindernissen worden overwonnen. Dankzij jouw stimulerende gesprekken 
(waar ook in Nederland) ging ik er weer in geloven en begon vol goede moed aan het 
volgende traject. 
Lex, na de verhuizing van Theo naar het hoge noorden nam je zijn directe begeleidende taak 
over. Tussen de werkzaamheden door werd er altijd wel een gaatje gevonden om te 
discussiëren over dit proefschrift en te filosoferen over de toekomst van de schildwachtklier 
procedure. Bij binnenkomst zei je vaak dat je maar even tijd had. Maar aangezien je jouw 
snelheid van spreken aanpast aan de hoeveelheid tijd die je hebt was alles gezegd op het 
moment dat je telefoon ging voor de volgende afspraak en je mij achterliet met fluitende oren. 
Mijn opleider Prof.dr. P.C. Levendag. Peter, al bij binnenkomst was de promotiedatum 
onderwerp van gesprek. Toen deze heel ver weg leek was het te danken aan jouw 
overredingskracht dat de schouders er toch weer onder werden gezet en de stoptrein de laatste 
halte kon bereiken. Ik vind het heel bijzonder dat ik veel tijd te besteden kreeg aan het 
afronden van een onderzoek wat in het geheel niets te maken heeft met Radiotherapie. 
Aangezien ik in den Haag de hoofd-hals oncologie als een van mijn aandachtgebieden heb 
hoop ik nog veel met je te kunnen samenwerken en eventueel iets samen te publiceren. 
Bert van Geel, het was jouw initiatief om de waarde van de schildwachtklier procedure in 
Rotterdam te onderzoeken. Bij jou kon ik altijd terecht voor een snelle en kritische 
beoordeling van de diverse manuscripten. Het mooiste compliment wat je me kon geven was 
je reactie toen je hoorde dat het onderzoek toch nog afgerond werd met een promotie. 
Rick Paul en Casper van Eijck, jullie waren de stimulerende chirurgen in het Zuider en 
Dijkzigt. Het was altijd erg prettig samenwerken en mede door jullie inzet werd de complexe 
procedure steeds minder complex. 
Marjan Menke, dankzij jouw inzet was het mogelijk een follow-up deel in dit proefschrift te 
maken. Tijdens de besprekingen heb ik veel bewondering gekregen voor jouw manier van 
blootleggen van het skelet van een artikel en vervolgens de verbouwing ervan.
De overige leden uit de promotiecommissie Prof.dr. I.H.M. Borel Rinkes, Prof.dr. J.W. 
Oosterhuis, Prof.dr. G.P. Krestin en Prof.dr. E.P. Krenning dank ik voor de interesse in het 
manuscript en de snelle beoordeling. 
De secretaresses van de afdelingen Radiotherapie en Chirugische oncologie. Natasha, soms 
voelde ik me wel schuldig als je alles uit je handen liet vallen om mij te helpen. Ook toen ik 
eenmaal Hagenees was kon ik je altijd bellen om iets voor me op te zoeken en naar me te 
mailen. Maar eigenlijk is het logisch dat je meer doet voor een Feijenoorder dan voor een 
Ajacied... Marja, een geboren secretaresse! Afspraken, vergaderruimtes, handtekeningen, 
adressen; voor alles kon ik je bellen en alles wist je voor me te regelen.  
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Mijn paranymfen, Annemarie Kragten en Stan de Kanter. Mijn oude “roommate” en voor 
enkelen mijn alter-ego Annemarie, vol weemoed denk ik aan de kopjes thee op de kamer en 
de gevoerde gesprekken over alle aspecten van het leven. Je luisterend oor was vaak al 
genoeg om het juiste spoor (weer) te vinden. Mijn broertje Stan, onovertrefbaar in sms’en en 
medesupporter van Feijenoord. Vaak zorgde je met een geintje per sms of mail weer voor de 
nodige ontspanning, al kostte het me een telefoontje naar Buckingham Palace. Volgend jaar 
op de Coolsingel? 
Mijn ouders, altijd vol interesse. Zonder medische achtergrond was het voor jullie niet altijd 
even gemakkelijk om mij te volgen. Maar de overgave waarmee jullie je verdiepten in de 
“schildwacht” maakte me trots. Hoewel we binnenkort toch echt Rotterdam gaan verlaten 
hoop ik dat we nog regelmatig een beroep op jullie mogen doen om op Kiki en Huib te 
passen.
En tenslotte Marcel, zonder jouw onvoorwaardelijke steun en geduld was het nooit 
afgekomen. Je vermogen om werk en gezin te combineren is ongekend. Daarbij is je kennis 
van de computer met alle software erg handig gebleken, vooral als ik weer eens een document 
“kwijt” was. Graag zou ik eens op jouw vrijdag om het hoekje willen kijken want het is 
hartverwarmend om je met Kiki en Huib bezig te zien. 
Ik ook van jou! 
Dankwoord
97
